

Cancer is still here, but so are we.

Irish Cancer Society
Annual Report 2020





Mary

Read her story about becoming an Advocacy Champion on page

12



Martin

Read about his song 'Day by Day' and fundraising for the Society on page

16



Luke

Read about his research work through his fellowship with the Irish Cancer Society on page

20



Shannen

Read her story about how she became the face of Daffodil Day 2020 on page

26



Annemarie

Read her story about working as a Night Nurse for the Irish Cancer Society on page

30



Contents

Vision, Mission and Values	2
Message from the Chair & CEO	4
Irish Cancer Society in Context	6
Report of the Board	
Strategic Review	9
Our Vision and Strategy	10
Mary Canavan - Personal Story	12
Priority One	14
Martin McDonnell - Personal Story	16
Priority Two	18
Luke Jones - Personal Story	20
Priority Three	22
Shannen Joyce - Personal Story	26
Priority Four	28
Annemarie Ward - Personal Story	30
Priority Five	32
Structured for Impact	34
How We Work	36
Fundraising Review	40
Financial Review	44
Structure, Governance and Management	47
Our Board	53
Financial Statements	57
Independent Auditors Report	58
Statement of Financial Activities	60
Balance Sheet	61
Statement of Cash Flows	62
Notes to the Financial Statements	63
Reference and Administrative Details	83

In a year of increased isolation we want to let the cancer community know that there are supports and services available.





Vision

By 2025, 3 out of 4 Irish cancer patients will survive their diagnosis and everyone affected by the disease will have access to world-class treatment, care and support.

In future, no one in Ireland will die from cancer.

Mission

The Irish Cancer Society is a community of patients, survivors, volunteers, supporters, health and social care professionals and researchers.

Together, we are working to save lives and improve the lives of people affected by cancer in Ireland.

The O'Donnell family from Rathgar take part in the Society's virtual Colour Dash.



Values

We are compassionate and caring.

Everyone's cancer journey is individual and we reflect that in everything we do. From the time you are diagnosed, right through to treatment and beyond, we provide personal support that is right for you.

We are inclusive.

It doesn't matter who you are or where you come from, we are here for you. We are working hard to ensure that everyone in Ireland has the same access to care and support during their cancer journey.

We demand excellence from ourselves and others.

We are constantly demanding more of ourselves and others on your behalf. We always believe there is room for improvement and we strive for excellence in all we do. Our services and decisions are informed by best quality knowledge, data and expertise.

We value collaboration.

Collaborating and working in partnership with world-class medical professionals, researchers, organisations and supporters helps us to deliver more. We want to be inspired and to improve by challenging ourselves and by benchmarking ourselves against world-class results. We build alliances and work with local communities and global partners to deliver best results.

We are accountable and transparent.

We work to the highest standards of governance and financial management. This means we are honest, ethical and efficient in our work. We hold ourselves accountable for the delivery of our goals and objectives.

We support sustainability.

We care about our communities and environment. We strive to be a sustainable organisation and minimise our impact on the world around us.



Message from our Chair and CEO

Brid & Averil



2020 was a year like no other. COVID-19 turned our world upside down for everyone and especially for people affected by cancer.

Imagine hearing the words “you have cancer” over the phone. Imagine going to treatment alone, without a loved one there to hold your hand. Imagine being in hospital, for days or weeks, with no visitors allowed. Imagine being afraid to see your family or friends, fearing the risk of infection. Imagine explaining your journey to a Garda on checkpoint duty on the way to your chemotherapy. Imagine not being able to be with the person you love as they go through all these challenges, not even in their final hours.

Sadly, many of you reading this won't have to imagine. You have gone through all this. At a time when emotional support and togetherness is most needed, COVID-19 has forced you to stay apart from those you love.

No one should have to go through cancer alone. Our priority in 2020 was to find ways to keep our cancer community together through this crisis; to provide support to people affected by cancer, even when we had to be apart.

We extended our Freephone Support Line during the peak of the crisis, introduced a new remote counselling service and developed new resources to help people stay well while staying home.

As nursing home and hospital restrictions took hold, our Night Nursing service allowed people to die at home with those they love. We recruited new Night Nurses to meet increased need, nurses like Annemarie who speaks to you on page 30. Thanks to Annemarie and all her colleagues, more people than ever before were cared for at home in 2020 and enabled to die surrounded by the people they loved.

Thanks to our community of volunteers, we were also able to continue services that other organisations had to pause. Our Volunteer Driver Service continued throughout the pandemic, safely bringing people to life-saving chemotherapy. More than 500 new volunteers joined our community, in various roles. Although some of our volunteers had to take a break from volunteering for public health reasons, our network of volunteers remain at the heart of the Society.

People up and down the country also stepped up in so many ways for people affected by cancer. Family, friends and loved ones of people with cancer made

phone calls, figured out Zoom, waved outside windows, wrote letters, sent cards, arranged deliveries and found ways to make sure we were together, even when apart.

Our fundraisers and supporters in communities and businesses across the country also found new ways to raise vital funds for people affected by cancer. In March 2020, when we were forced to cancel Daffodil Day, the people of Ireland came together with an immense swell of support to raise millions through a grassroots campaign. People around the country, people like Martin on page 16, found creative ways to fundraise and show their support.

We write this just after Daffodil Day 2021, which was an overwhelming success in spite of the continuing essential public health limitations. Thanks to the generosity of individuals, communities and businesses up and down the country the Irish Cancer Society will continue to be there for people affected by cancer in 2021 and beyond, providing vital supports and funding lifesaving research. We are hugely indebted to everyone who played a part in this outcome, including our sponsor Boots and the Late Late Show team.

In 2020 we worked hard to ensure cancer did not become 'the forgotten C' of the crisis. This included making sure that the needs of people affected by cancer were considered by decision makers.

COVID-19 and its legacy pose a real threat to the progress made in increasing cancer survival in Ireland. People have the best chance of surviving cancer when it is caught early. COVID-19 is contributing to delayed diagnoses in many ways: pausing screening services, cancelling or delaying "non-urgent" care, and reducing healthcare attendance. We've worked to mitigate those impacts, including through our advocacy and awareness campaigns, and this continues to be a priority.

We will continue to shine a light on the needs of people affected by cancer. Our new volunteer Advocacy Champions, like Mary whose story is on page 12, will be a vital part of that work.

After the pandemic, we need to "build back better" than before – with increased investment, better models of care, and improved outcomes. The additional €32 million provided for cancer services in Budget 2021, as a result of our pre-budget campaigning, will be part of the solution.

2021 is also an opportunity for us to advance Irish cancer research. COVID-19 reduced research activity, with labs closing for a period and clinicians moved to other work. Despite this, we continued to support researchers like Luke, whose research is described on page 20, to develop new treatments and improve outcomes. This year, we are accelerating our investment in research with a doubling of our support for cancer trials, to help catch up on lost time and enable more people affected by cancer to benefit from innovative treatments and care.

2020 saw the launch of our new strategy. This strategy sets out a vision that by 2025, 3 out of 4 Irish cancer patients will survive their diagnosis and everyone affected by the disease will have access to world-class treatment, care and support. Our ambition is that in the future, no one in Ireland will die from cancer.

COVID-19 and its long legacy have challenged that vision – and this makes our strategy to achieve it even more necessary than ever before.

Responding to the way in which cancer care and survival has changed as a result of COVID-19 will frame much of what we do in coming years. In tackling this legacy however, we also cannot forget about the wider advances we need to make.

An important part of our strategy is making sure world-class cancer care, treatment and support are available for everyone affected by cancer, at every stage of their journey. In 2021 we are working to increase the supports and services available for children and young adults affected by cancer, whose particular needs are underserved at present. We will also improve the supports available for survivors of cancer, helping them manage the physical and emotional aftermath of a cancer experience.

2020 was a devastating year for people affected by cancer. But it also showed how resilient, creative and dedicated our cancer community is. When we come together as patients, survivors, volunteers, supporters, health and social care professionals and researchers, we can achieve incredible things for everyone affected by cancer.

We can build back better. With your support, we will deliver a future where no one in Ireland dies from cancer and all survivors have the support they need to live life to the full.



Handwritten signature of Brid Horan in blue ink.

Brid Horan
Chair

Handwritten signature of Averil Power in blue ink.

Averil Power
CEO

Irish Cancer Society in Context



Everyday 120 people across the country hear the words “you have cancer”. That’s an estimated 44,000 people in Ireland receiving a cancer diagnosis each year.

The Irish Cancer Society believes every single patient must have access to the support they need, when they need it most. We understand how cancer can affect every aspect of a person’s life and we are there for patients and their loved ones at every stage.

From the moment of diagnosis, a person in need of support can drop into one of our 13 Daffodil Centres. There, they will find nurses and trained volunteers who can help them to understand their diagnosis and treatment plans in plain English, avail of education that will empower them to stay well during their cancer treatment, or just find a listening ear.

Our specialist Cancer Nurses are on hand through our Freephone Support Line to speak to anyone who has a concern about cancer, whether they are a patient, a loved one of someone with cancer, or have a question about prevention and early detection. Our community of survivors are also available to provide emotional support through our Survivor Support Network.

The Society is there in practical ways too. For example, to help people get to and from chemotherapy, our Volunteer Drivers are available nationwide. We are also there for people at the end of their lives, to provide palliative care in their own homes.

We work to improve public services for people affected by cancer. We advocate for systemic change and improvement in public policy, care and services. We also fund lifesaving and life-changing research, and support the Irish research community, to bring forward the day where no one dies from cancer.

2020 was a challenging year for everyone, but particularly for cancer patients and their families. Treatment plans were interrupted and rescheduled, and social distancing requirements have forced patients to stay physically apart from family and friends at a time when they badly need emotional support.

From the outset, the Irish Cancer Society has been committed to doing everything we can to reduce



See more about

Our Priorities
on pages 14-34



7,700

Our Night Nurses provided approximately
7,700 nights of care in 2020



Left: Panto Dame, Joe Conlan pictured at the Gaiety Theatre to launch the Society's 'Living Well & Beyond with Cancer' conference

Right: Pictured, Dr Arman Rahman, Translational Research & Engagement Manager at Precision Oncology Ireland. In 2020, the Society continued funding of €500,000 over 5 years to the POI Consortium, to develop an innovative tissue imaging platform that can help researchers better understand what treatments may be more effective for certain cancer patients using indicators known as biomarkers.

COVID-19's impact on people affected by cancer, by remaining flexible and responding to new needs as they emerge. As a patient focused organisation, our key priority throughout has been to ensure that patients and their families have the support they need, when they need it most.

- Our Night Nurses continued working night after night, providing end of life care to patients in the comfort of their homes, surrounded by loved ones. To meet increased demand for patients to die at home, we recruited additional Night Nurses nationwide. In 2020 alone, our Night Nurses provided approximately 7,700 nights of Night Nursing across Ireland.
- We responded to the new challenges posed by COVID-19 by introducing a remote counselling service available for patients and families, to help them to deal with the emotional impact of a diagnosis.
- Our Freephone Support Line: 1800 200 700 continued, ensuring patients had access to a listening ear, to get advice, support and cancer information.
- We developed an online hub about coronavirus and cancer. This provided tailored and trusted information about staying well at home, benefits and entitlements, and reduced the fear of people affected by cancer.

- The Society's Volunteer Driver Service continued throughout lockdowns ensuring cancer patients nationwide had access to free transport to and from chemotherapy appointments.
- Through our advocacy efforts, we continued being the voice of the cancer community, ensuring that their needs were at the heart of decision making in the health and political system. We advocated on issues such as screening, diagnostics and vaccination priorities to ensure cancer does not become 'the forgotten C' during COVID-19.

None of our work in 2020 would have been possible without the exceptional support and generosity we have received from the Irish public. Our supporters embraced the challenges that 2020 posed and through their extraordinary individual and virtual efforts, they continued to raise vital funds to support cancer patients and their families.

Their determination is a true testament to the dedication and generosity of our supporters. Although 2020 was an extremely challenging year, it also proved the strength of the community of the Irish Cancer Society. A community of friends, patients, survivors, volunteers, supporters, researchers and health care professionals, determined to help anyone affected by cancer in Ireland.



Our Priorities

Healthy Living

Fewer preventable cancers

We will influence Government policy and laws so that everyone has the best chance of living a life free from cancer. We will invest in research that uncovers new ways to prevent cancer. We will provide advice to those who need it.

Catching Cancer Early

More cancers caught early

We will give people the best chance of surviving cancer. We will lead advocacy campaigns, innovate services, fund research, and work in partnerships that will eliminate the survival gap between Ireland and other European countries.

Treating Cancer

World-class cancer treatment for everyone

We will lobby Government so that all cancer patients are given timely access to treatments that will work best for them. We will reduce the fear of cancer through our support services and invest in research that has the potential to transform lives.

Living Well

Living well after treatment

We will make sure the emotional, physical, financial and practical needs of those who have undergone cancer treatment are met. We will provide services that will directly support people, so they are better able to cope with the impact of cancer. We will undertake research that will help us improve cancer patients' quality of life.

End-of-Life Care

Holistic support for people dying from cancer

We will ensure people dying from cancer have access to the full range of supports needed by them and their families. We will drive changes from Government that will mean more people can die at home. We will prioritise research that guides the development of our own supports and informs our advocacy to improve public services for people dying from cancer.

15 year old Aaron Kinsella attends the Society's Christmas tree light up in memory of his grandad Robert. The tree was lit with 9,000 lights to commemorate the 9,000 lives lost to cancer in 2020.

Strategic Review



See more about

Our Values
on page 3

Our Vision and Strategy

2020 saw the launch of the Irish Cancer Society's new strategy.

This strategy sets out a vision that **by 2025, 3 out of 4 Irish cancer patients will survive their diagnosis and everyone affected by the disease will have access to world-class treatment, care and support. In future, no one in Ireland will die from cancer.**

As a community of patients, survivors, volunteers, supporters, health and social care professionals and researchers we are working to save lives and improve the lives of all people affected by cancer in Ireland across every stage of the cancer journey:

Healthy Living:
Fewer preventable cancers

Catching Cancer Early:
More cancers caught early

Treating Cancer:
World-class cancer treatment for everyone

Living Well:
Living well after treatment

End-of-Life Care:
Holistic support for people dying from cancer

Progress will be made across all of our priority areas through our three pillars of activity: **advocacy, services** and **research**. This work is enabled by our fundraising efforts and having the right people, processes and technology in place to support our progress and performance.

Integrating our COVID-19 response into our strategy

Our strategy is adaptable by design. In order to achieve our vision, we must be able to respond quickly and effectively to the changing needs of the cancer community in Ireland.

This adaptability was put to the test immediately in 2020, with the devastating coronavirus pandemic. COVID-19 disrupted all our lives and poses immense challenges for people affected by cancer. Our COVID-19 response was immediate, and was integrated into our strategy delivery. Every activity we conducted in 2020 to progress our strategy was considered in the context of COVID-19 and adapted where necessary, whilst still building toward our long term goals.

COVID-19 has increased the practical, financial and emotional burden of cancer; the need for trusted and reliable information; and the necessity to advocate for treatment and services to mitigate the impact of COVID-19 on cancer outcomes. This meant that while we have worked across all of our strategic areas in 2020, we have particularly focused on our 'Treating Cancer' and 'Living Well' priorities. Given COVID-19's impact on early detection and diagnosis, 'Catching Cancer Early' was a focus area in 2020 which will grow in significance into 2021 and beyond.

COVID-19 impacted, and continues to impact, every one of our priority areas under the strategy – from cancer prevention through to end-of-life care– but it has not stopped our progress toward a future where no one in Ireland will die from cancer.



Cancer survivor, Shannen Joyce,
and her daughter Róisín



See more about

Our Priorities

on pages 14-34

Mary

Personal Story

I was diagnosed with breast cancer in 2018, aged 32 and just 9 weeks pregnant. I can barely remember the words that came out of my consultant's mouth when he told me I had breast cancer. It was such a complete shock.

I had never heard of anybody my age having cancer, I was totally unprepared and devastated and I was really scared as I had just found out I was pregnant with my first child. It was so tough telling friends and family the bittersweet news that I was pregnant and had breast cancer.

My treatment included a lumpectomy surgery followed by a total of 6 months chemotherapy – 4 months whilst I was pregnant and another 2 months after my son was born.

Having breast cancer myself at such a young age has affected me so deeply and made me determined to help support and advocate for cancer patients in Ireland, so in 2020 I decided to become an Irish Cancer Society Advocacy Champion

As a voluntary Advocacy Champion, I work closely with the Society's advocacy team to ensure that the needs of cancer patients, survivors and their loved ones are heard at all levels of Government. Some of the ways I support

the Society's advocacy efforts include: writing to politicians and government departments, meeting with local politicians and amplifying Irish Cancer Society advocacy campaigns on social media.

Becoming an Advocacy Champion has been a great way for me to make a difference to the lives of people affected by cancer in Ireland, it is a privilege to help in any way that I can.

**Mary Canavan,
Advocacy Champion**



See more about

Our Advocacy Network
on page 35



As a voluntary Advocacy Champion, I work closely with the Society's advocacy team to ensure that the needs of cancer patients, survivors and their loved ones are heard at all levels of Government.



Healthy Living

Our Goal

We are working for a future
with fewer preventable cancers.

To achieve this

we will influence Government policy and laws so that everyone has the best chance of living a life free from cancer.

We will invest in research that uncovers new ways to prevent cancer. We will provide advice to those who need it.

The impact we've had in 2020

Our pre-Budget submission called for an increase in tax on tobacco, and Government investment to support healthy living. Our efforts resulted in Government announcing in Budget 2021, a 50c increase in excise duty on cigarettes and a significant increase in expenditure on walking and cycling infrastructure to support physical activity.

Legislation to ban the sale of **e-cigarettes** to under 18s, and further restrictions on e-cigarette advertising, were included in the Programme for Government after our lobbying and we will work to ensure that those commitments are met.

We have invested in new **research** which can help prevent cancer from ever developing. As part of our John Fitzpatrick Fellowship, supported by Sanofi, Dr Emma Allott is currently researching factors which may cause or protect against prostate cancer, one of the most common cancers in men in Ireland. Funded by the Society, Beth McKeague examined the effect of a familial cancer diagnosis on the health behaviours of family members, and her published¹ findings will help to find ways to support family members of cancer patients to reduce their risk of developing cancer themselves.

We believe that a **Government-led national approach to smoking, obesity, physical activity and alcohol** is needed. In a step toward this, we successfully transitioned our community prevention programmes to other State providers. National health service leadership of these programmes will allow more people to benefit from the evidence and expertise generated from our years of support at a community level.

In 2021 we will...

- ★ Continue to campaign for the full implementation of the Public Health (Alcohol) Act including measures such as minimum unit pricing and labelling to highlight the links between alcohol and certain cancers.
- ★ Push Government to go further on proposed e-cigarettes legislation, to tackle the inappropriate targeting of young people by e-cigarette advertising and flavours.
- ★ Contribute to the production of the first ever National Stop Smoking Clinical Guidelines by the HSE, to allow every person in Ireland access to supports to quit smoking.
- ★ Press for a blanket catch-up for the HPV vaccination programme in schools, after COVID-19 disrupted roll-out, to ensure children are protected from HPV-related cancers.
- ★ Publish Irish Cancer Society funded research by Prof Josephine Hegarty on patient and healthcare professional experiences of cancer genetic services. Approximately one in ten cancers has a genetic cause, and this research can be used to advance and improve genetic services in Ireland.



Approximately 1 in 10 cancers has a genetic cause, and new research can be used to advance and improve genetic services in Ireland.

1. McKeague, B. and Maguire R., (2020), "The effects of cancer on a family are way beyond the person who's had it": The experience and effect of a familial cancer diagnosis on the health behaviours of family members, *European Journal of Oncology Medicine*, 51, 101905, <https://www.sciencedirect.com/science/article/pii/S1462388921000119>

I wanted to give something back to them so I decided to release the song 'Day by Day' in October 2020 and to donate all proceeds from the sale of the single to the Society.



Martin

Personal Story

I was just 18 and studying for my Leaving Cert when my Mam Brigid was diagnosed with breast cancer in December 2019. Her diagnosis came as a huge shock to our whole family and it left me feeling pretty helpless.

I'm a singer/songwriter and decided to write a song 'Day by Day' as a tribute to my Mam, in support of her going through the disease, and as a way of understanding what I was feeling. Getting something on paper seemed like the best way to do that at the time.

Mam's cancer diagnosis was tough on the whole family, but the support that we all received from the Irish Cancer Society was absolutely incredible, they

really helped my family and me through a difficult time. I wanted to give something back to them so I decided to release the song 'Day by Day' in October 2020 and to donate all proceeds from the sale of the single to the Society.

I have been blown away by the support from the public, the fundraiser has been a phenomenal success, and has raised over €4,000 so far for cancer patients and their families across Ireland. I have enjoyed fundraising

for the Irish Cancer Society because I have seen first-hand the support they give to families every day in Ireland and I know how important their work is on all levels. Cancer is such a negative word and with me being so young I felt helpless, but fundraising let me focus on a positive with cancer. I'm so glad I could mix my passion for music with supporting others when they need it most!

**Martin McDonnell,
Fundraiser**



See more about

**Our fundraising campaigns
in the Fundraising Review**

on page 40

Catching cancer early

Our Goal

We are working for a future
where more cancers are caught early.

To achieve this

we will lead advocacy campaigns, innovate services, fund research, and work in partnerships that will eliminate the survival gap between Ireland and other European countries.

We will give people the best chance of surviving cancer.

The impact we've had in 2020

COVID-19 poses a real threat to progress which has been made toward catching cancer early. Mitigating that threat has been the focus of our work under this priority for 2020. It will continue to be our focus into 2021.

In March 2020, **screening services** were paused. Just over 300,000 fewer people were screened in the first three quarters of 2020 than in the same period in 2019². We know that screening saves lives and we worked tirelessly to push to get screening back up and running, safely, over the summer. Our attendance at the Oireachtas Special Committee on COVID-19 Response highlighted this issue to TDs and Senators, increasing the pressure for normal patterns of screening, diagnosis and treatment to resume.

We have consistently spoken about how, post COVID-19, we need to **"build back better"** than before – with increased investment, better models of care, and improved outcomes.

With screening, building back better includes increasing uptake across all screening services. Our **research**³ previously found that fear and fatalistic beliefs about cancer lead to lower take up of bowel screening. This year we funded two follow-on research projects to build on that insight, and identify the actions which can be taken to increase uptake and improve bowel screening in Ireland.

Our research into healthcare attendance led us to understand the scale of the **impact of COVID-19 on early diagnosis**. Our survey found that 1 in 4 people did not attend a GP or hospital appointment when they needed to during the first lockdown. Reasons for this included not believing their condition was serious enough, fear of contracting COVID-19 or their appointment was cancelled. From the beginning of April, through to the end of the year, we spoke publicly about the importance of contacting your GP with any healthcare concerns and worked to reduce the worry associated with seeking medical care.

Pausing invitations for screening will have resulted in approximately 450 cancers and 1,600 pre-cancers going undetected since March. Unless typical patterns of cancer screening, diagnosis and treatment return there is a serious risk that delays and backlogs could lead to avoidable deaths.

Rachel Morrogh, Director of Advocacy and External Affairs, to the Oireachtas Special Committee on COVID-19 Response, July 2020

Our Lung Cancer Awareness campaign in September was one example of this, which resulted in more people attending their GP with potential lung cancer symptoms. Electronic referrals by GPs to Rapid Access Lung Clinic in September were the highest since February 2020, with a 29% increase in referrals from August to September.⁴

In 2021 we will...

- ★ Keep the impact of COVID-19 on the national and political agenda so that action on waiting lists for cancer services remains a priority.
- ★ Advocate for dedicated cancer infrastructure, to build a sustainable and resilient cancer system that catches cancer early.
- ★ Work with GPs and healthcare providers to ensure people with signs of cancer do not delay in seeking medical advice.
- ★ Increase understanding of the signs and symptoms of cancer and work to increase uptake of existing screening services through our national campaigns and community outreach initiatives.
- ★ Drive political momentum to fully restore cancer screening programmes.
- ★ Invest in a new pilot project to address the needs of patients with a genetic or high familial risk of cancer. This project will research patient needs, identify gaps in existing services, and pilot a clinical psychology service for patients with genetic or high familial risk of cancer.

2. National Screening Service (2021), Response to Parliamentary Questions [PQ11925-27/21]

3. Irish Cancer Society-funded research, undertaken by Dr Nicholas Clarke and carried out between the National Cancer Registry of Ireland and University College Cork; Fear behind low bowel screening figures as one-in-four say cancer diagnosis is death sentence | Irish Cancer Society

4. eHealth Ireland/ NCCP, (2020), eReferrals data for Cancer Services Statistics, available online at <https://www.ehealthireland.ie/a2i-hids-programme/ereferral/latest%20data/nccp%20referral%20data/>

Luke

Personal Story

I have been working in childhood leukaemia since 2012. Originally from Sydney, Australia I moved to Ireland in late 2018 and in 2019 joined Prof Jonathan Bond's research group at Systems Biology Ireland, to gain expertise in systems biology and to allow pursuit of innovative insights into acute leukaemias.

I was recently awarded funding from the Irish Cancer Society and began working on a new project within SBI to identify more effective treatments for paediatric blood cancers. Our research group is co-located at Children's Health Ireland (CHI), Crumlin. This allows us to gain valuable insight into important clinical issues, and to keep outcomes for paediatric patients at the forefront of our work at all times.

My research is particularly focused on a type of leukaemia called acute myeloid leukaemia

(AML). AML accounts for approximately 20% of all paediatric leukaemias and is the leading cause of blood cancer-related mortality in childhood. Survival rates for paediatric AML have improved dramatically in recent decades, now exceeding 60%, however this is mostly due to improvements in patient care rather than the introduction of new therapies.

Through this fellowship, I want to find more precise treatment options that target the cancer without damaging normal cells by identifying the 'Achilles

heel' of blood cancer cells. I believe that using systems biology will help identify new drug combinations that will provide better, safer treatments and improve outcomes for paediatric patients with leukaemia. I am extremely excited about developing our patient and public involvement strategy throughout the fellowship, especially the development of a patient advisory group. It will be a privilege to work closely with, and learn from, patient advocates throughout this fellowship.

**Luke Jones,
Researcher**





Through this fellowship, I want to find more precise treatment options that target the cancer without damaging normal cells by identifying the 'Achilles heel' of blood cancer cells.

Treating cancer

Our Goal

We are working for a future
with world-class cancer treatment
for everyone.

To achieve this

we will lobby Government so that all cancer patients are given
timely access to treatments that will work best for them.

We will reduce the fear of cancer through our support services
and invest in research that has the potential to transform lives.

The impact we've had in 2020

To achieve a future with world-class treatment for everyone, cancer care needs to be top of the agenda for all national leaders.

In the lead up to the 2020 General Election, we worked to build awareness and understanding across all of the political parties, and gain commitment to our suite of policy proposals. The three largest parties included the majority of these proposals in their manifestoes. Ten of the issues, and solutions, we highlighted were incorporated into the **Programme for Government**. Our advocacy efforts also led to a commitment by the Minister of Health to fully implement the National Cancer Strategy – and to fund it.

In September, we launched our pre-budget submission and continued engaging with politicians and policy makers, as we had done all year, to make sure cancer services are properly funded. As a result of our efforts, **Budget 2021** delivered the full amount we campaigned for: €20 million allocated to the National Cancer Strategy and an additional €12 million dedicated to dealing with the impact of COVID-19 on cancer services. This is an unprecedented increase in funding, and will help Irish cancer services to “build back better” after COVID-19.

In no other year has our focus on reducing the fear and worry associated with cancer treatment been as important as in 2020. Our **Freephone Support Line** provides confidential, trusted advice and support by trained nurses, for people affected by cancer. During the first wave of the pandemic, we extended our Freephone Support Line opening hours to provide a 7 day a week service, and redeployed staff who could provide additional information on social welfare, employment, housing and finances. April and May saw a 64% increase in calls answered, compared to January and February. Over the year, our Freephone Support Line answered more than 8,000 calls and emails in 2020, an increase of 6% from 2019.

She was my powerhouse of support. She was there for me whenever I needed her.

Louise Collins, speaking about her counsellor, provided by the Irish Cancer Society

Having access to accurate, trusted information about cancer is another way to reduce the fear and worry of treatment. Our **website** saw 1.8 million unique visitors in 2020, up 29% from 2019. We created an online coronavirus and cancer hub, to meet the needs of people affected by cancer. This included

information on benefits and entitlements, financial supports, wellbeing advice, as well as up-to-date insights on the research about coronavirus and cancer.

Our strategy recognises that world-class treatment for cancer is not just a clinical matter. The psychological burden of treatment can be immense, and support for this must become part of the normal model of care for people with cancer. This year saw that psychological burden increase, as people undergoing treatment were unable to rely on their usual support networks. We introduced a **remote counselling service** in 2020 which directly delivered over 900 counselling sessions to people affected by cancer, in addition to nearly 8,000 sessions (remote and face-to-face) funded through our affiliate programme. Our partnership with the National Cancer Control Programme (NCCP) and Cancer Care West was established, providing a pathway for people affected by cancer to access clinical psychology and psychiatry services.

Our strategy emphasises partnership. The best outcomes for people affected by cancer come when all in the cancer community – patients, survivors, healthcare professionals and volunteers – work together. In this spirit, during the first wave of the pandemic, our **Irish Cancer Society Daffodil Centre nurses** redeployed to acute cancer units to assist with the response to COVID-19. Our nurses, working with hospital staff, helped ensure that chemotherapy and radiotherapy could continue, safely, and that the fear and uncertainty of treatment during COVID-19 was reduced for patients.

We continue to provide practical support to people undergoing treatment for cancer. Our **Volunteer Driver Services** operated throughout the year transporting close to 1,600 people to almost 12,000 chemotherapy and related appointments. 99% of requests for a drive were fulfilled, thanks to the dedication of our volunteers. This included 270 new volunteer drivers on-boarded in 2020 as many of our long-standing volunteers had to step back temporarily from volunteering due to COVID-19. We look forward to welcoming them back to volunteering very soon.

Clinical trials are critical to develop new treatments and interventions, and represent an opportunity for many people affected by cancer to gain access to potentially lifesaving and life-changing treatment. COVID-19 restrictions meant that from March to June access to new clinical trials stopped, but existing trials continued. Our investment of €500,000 in Cancer Trials Ireland (CTI) in 2020 contributed to almost 1,000 new patients participating in CTI clinical trials and research studies overall in 2020, as well as the continuing participation of over 3,000 patients. Advances in oesophageal cancer treatment, increased understanding of bowel cancer recurrence, improvements in ovarian cancer treatment and fertility options for women affected by breast cancer, are just some of the results from the trials funded.

We want world-class treatment for everyone. To achieve this we fund life-changing research to treat cancer, in particular translational research.

Translational research is sometimes called “bench to bedside” and is research which “translates” basic scientific or lab based research into new treatments, therapies or procedures which can directly improve the lives of patients. We awarded €1.5 million in new research under our Treating Cancer goal, including over €700,000 in translational research this year. This funding included Dr Luke Jones’s translational research in leukaemia, Adele Connor’s PhD research into ovarian cancer and Prof Lydia Walsh’s research project in immunotherapy for ovarian cancer.

We also awarded our Clinician Research Leadership Awards to Dr Dearbhaile Collins and Dr Shirley Potter, providing them with dedicated research time to make strides in lung cancer and melanoma clinical research.

Our strategy also recognises that a **strong, multidisciplinary research environment** in Ireland benefits all. We conducted research environment development activities – two funding webinars, four research training events and 28 research talks – to help researchers in Ireland gain European funding, return to research, or disseminate their research outcomes. We also launched our Decoding Cancer podcast series, to help bring research findings and insights directly to people affected by cancer.

In 2021 we will...

- ★ Continue to track and monitor the impact of COVID-19 on cancer services, so that we can take immediate action to mitigate the worst of its effects.
- ★ Secure continued increases in Government funding for cancer services to improve cancer survival and the availability of services to improve the quality of that survival.
- ★ Expand our pre-treatment workshops for patients to provide information, advice and support to every patient undergoing treatment for cancer.
- ★ Increase the digital delivery of our services including virtual patient workshops, increased online content, and video Support Line calls, so we can reach more people around the country.
- ★ Expand and grow our counselling services through virtual counselling and partnerships with cancer centres.
- ★ Invest at least €500,000 into cancer trials in Ireland to provide patients access to ground-breaking treatment.
- ★ Invest a further €700,000 into translational research to ensure laboratory breakthroughs reach Irish patients.
- ★ Fund research into niche, underserved or specialist areas of cancer, so that our research can benefit all people affected by cancer.

Treating Cancer in numbers*

€32 m

secured in Budget 2021 for cancer services

12,000

drives to and from cancer treatment provided

8,000

Freephone Support Line calls and emails answered

8,900

counselling sessions provided
(direct and funded through our affiliate programme)

3,000

patients participating in cancer trials with Cancer Trials Ireland

€1.5 million

invested in new research to treat cancer
(out of **€2.4 million** total invested in research)

1.8 million

unique visitors to cancer.ie

* All numbers are approximates





Above: Irish Cancer Society Research award winners Jessica Walsh and Gráinne Shiel with the Society's Director of Research, Dr Robert O'Connor.

Donate to support
us at [Cancer.ie](https://www.cancer.ie)

Apart



But not alone.

**Freephone
1800 200 700**

Monday to Friday
9.00am – 5.00pm

For information on any cancer related issue, including coronavirus, call the Irish Cancer Society's Support Line.



Support
Line

Shannen

Personal Story

I was first diagnosed with cancer aged 19 and underwent extensive treatment. At the time my parents shielded me from so much of the worry and it was all about me, I had to drop out of college, I couldn't go on nights out. I remember my hair falling out felt like the end of the world.

Unfortunately, my cancer re-occurred when I was 24, and had just become a mum to my wonderful little girl Róisín. Now I was a mother myself and my fear was not for myself but for my little girl. It was gut-wrenching to miss out on time with her when I was having treatment, or when I was too unwell to do everyday things like dress her. But Róisín was also my driving force – the reason I got out of bed each day.

I began sharing my cancer journey with thousands on Instagram and was honoured to be asked to be the face of Daffodil Day 2020, to share my cancer experience to support others in need.

My cancer unfortunately returned for the third time in 2020 and I underwent further rounds of chemotherapy. I recently had a second stem cell transplant in St James's Hospital Dublin, which I'm currently recovering from. This time has been exceptionally hard, with the additional worry of COVID-19, and having to spend long periods of time in hospital alone.

I'm so lucky to have an incredible support network, particularly my partner Barry, daughter Róisín, my very close family, and of course my dog Charlie!

I hope that by sharing my story, I will help and inspire others going through cancer.

I want to be a voice for men and women, young and old. I want people to know that cancer does not discriminate on the basis of your age or gender. Cancer can come knocking on anyone's door at any time. This is why it is so important to have the Irish Cancer Society and the services they offer, the research they do and the support they give. From Night Nursing, the Volunteer Driver Service, to the Survivor Support programme they all make a huge difference to the thousands of people impacted by cancer in Ireland every day.

**Shannen Joyce,
Cancer Survivor**



I began sharing my cancer journey with thousands on Instagram and was honoured to be asked to be the face of Daffodil Day 2020, to share my cancer experience to support others in need.



Living well

Our Goal

We are working for a future
where everyone affected by cancer lives
well after treatment.

To achieve this

we will make sure the emotional, physical, financial and practical needs of those who have undergone cancer treatment are met.

We will provide services that will directly support people, so they are better able to cope with the impact of cancer.

We will undertake research that will help us improve cancer patients' quality of life.

The impact we've had in 2020

Cancer takes so much from people – we don't want it to take away the chance for a biological family too.

That's why, in support of our Living Well priority we have pushed hard this year to support fertility preservation for people undergoing cancer treatment. Our engagement with clinicians and policy makers restored onco-fertility services, after original COVID-19 plans deemed them "non-essential". We also published **fertility preservation** policy recommendations in June and hosted an information session for people affected by the issue to understand their options and available services.

In August, we launched the **Childhood Cancer Fertility Project**, in partnership with the Merrion Fertility Clinic, which delivers fertility treatment supports and methods to preserve fertility for children with cancer in Ireland. The programme has commenced fertility assessment and planning for those who have completed treatment as well as preserving future fertility options for children embarking on treatment. This is the first programme of its kind in Ireland and a huge step in helping children and young adults to live well after cancer.

We continued to advocate for practical changes which make a big difference to people living after cancer. From helping to ensure insurers covered COVID-19 screening for cancer patients in private hospitals, to successfully advocating for the automatic renewal of medical cards for people affected by cancer during the pandemic, we worked to reduce the burden of cancer.

The experience of surviving cancer, especially during COVID-19, can be isolating and hard to navigate. We hosted our first ever virtual survivorship conference, **Living Well With and Beyond Cancer** in September, with over 1,130 registered attendees. The presentations, information sessions and workshops are all available on cancer.ie.

Research into the experience and needs of survivors of cancer is under resourced in Ireland and globally. We invested €400,000 in **survivorship research** in 2020 to help bridge that gap. This research covers both clinical needs and experience, and wider psychosocial research such as that of Christina Gleeson from NUI Galway who was funded by us to research the psychosocial impact on quality of life for Lynch Syndrome patients in Ireland.


This year we also launched the **Women's Health Initiative**, supported by the National Cancer Control Programme (NCCP). This is a patient led programme,

which combines research, clinical care and supports to improve the management of symptoms and side effects of cancer and cancer treatment for women affected by gynaecological and breast cancers. The initiative provides the first dedicated clinics for female cancer survivors nationwide, and will serve as a model of care for wider roll-out for all survivors in the future.

The **financial burden of cancer** starts during treatment but can knock-on and impact the quality of life after cancer. Our Travel2Care fund (providing financial support to people to travel to cancer treatment) and our Children's Cancer Fund distributed almost €500,000 in supports in 2020 to ease this burden.

In 2021 we will...

- ★ Roll-out a new post-treatment patient education programme, to empower all patients finishing treatment with the information and support they need to live well after cancer.
- ★ Launch our research, conducted by the ESRI, into the experience of people returning to work after cancer, and engage with employers, trade unions and policy makers to improve the experience.
- ★ Provide direct employment, finances and benefits advice to people affected by cancer.
- ★ Further increase the information and content we provide about the resources and supports available for people living after cancer.
- ★ Conduct a national patient experience survey to better understand the experience of people living after cancer and use these insights to develop new services and campaign for change.
- ★ Research the real cost of children's cancer and advocate for Government supports to reduce the financial burden on parents and families.
- ★ Invest €1.2 million into survivorship research, to improve the lives of people living with and after cancer.
- ★ Launch a Men's Health Initiative, modelled on the Women's Health Initiative, to ensure access to world-class care for all survivors of cancer.
- ★ Invest in a Lymphoedema Early Detection Project in Limerick to improve the long term wellbeing of people with cancer related lymphoedema, a side effect of many cancer treatments.

An illustration of a two-story house at night. The sky is dark blue with a full yellow moon and several white stars. The house has a blue upper section and a red brick lower section. There are three windows on the upper floor and one on the ground floor, all with yellow light and scalloped curtains. A person wearing a blue uniform, a face mask, and a headband stands on a small porch in front of a brown door. They are holding a black bag and a mobile phone. A large dark tree is on the right, and some bushes are at the bottom.

Before I joined the service
I really had no idea how
rewarding I would find the job,
being able to give so much
comfort and reassurance to
both patients and families
during a very difficult time.

Annemarie

Personal
Story

I became an Irish Cancer Society Night Nurse in May 2020, having previously worked as a practice nurse in a number of GP practices.

When I heard of the increased demand for at home palliative care due to the pandemic, I decided to apply to become an Irish Cancer Society Night Nurse. Before I joined the service I really had no idea how rewarding I would find the job, being able to give so much comfort and reassurance to both patients and families during a very difficult time.

There is so much variety working as a Night Nurse,

no two cases are the same, which makes the role so interesting. There is so much job satisfaction knowing that our patients and their families welcome us into their homes and put their trust in us to ensure their loved one is comfortable, pain free and most of all peaceful in their last hours.

Working as a Night Nurse has opened my eyes to the need for people to choose where to die. Because of the Night Nursing service many

families can feel comforted at the prospect of their loved ones remaining in their own home, safe in the knowledge that their passing from this world will be dignified, pain free and peaceful.

**Annemarie Ward,
Night Nurse**

End of life care

Our Goal

We are working for a future
where there is holistic support for
people dying from cancer.

To achieve this

we will ensure people dying from cancer have access to the full range of supports needed by them and their families.

We will drive changes from Government that will mean more people can die at home.

We will prioritise research that guides the development of our own supports and informs our advocacy to improve public services for people dying from cancer.

The impact we've had in 2020

COVID-19 resulted in an increased demand for our Night Nursing services.

With COVID-19 restrictions in place in hospitals and nursing homes, many more people at end-of-life wanted to die at home with their loved ones. Our Night Nursing service allowed this to happen.

We provided approximately 7,700 nights of Night Nursing to people with cancer in 2020, up 13% from 2019. This care allowed 2,229 cancer patients to die at home, with their loved ones. This is a 20% increase in the number of patients with cancer cared for compared to 2019.

We recruited additional Night Nurses to meet rising demand, and to manage reduced availability of Night Nurses due to COVID-19. Despite this recruitment and the dedication and commitment of our Night Nurses, we were not able to meet 11% of requests for the service. Continued recruitment of skilled Night Nurses and expansion of the service to meet increased needs is an ongoing priority into 2021.

We also continue to invest in **research** into improving palliative care and the quality of life of people at end-of-life, through funded studies into areas such as how to support people with metastatic bone cancer to be physically active, or how to improve prescription practices for patients undergoing palliative cancer treatment.

We have advocated for people who are terminally ill, successfully securing the **extension of medical cards** for people with a terminal illness to those with a 24 month prognosis. We also responded to the Oireachtas Justice Committee's public consultation on the Dying with Dignity Bill, advocating for a consultative approach which places patients at the heart of any decision making.

In 2021 we will...

- ★ Retain our skilled and dedicated Night Nursing staff, and recruit more nurses to meet increased demand.
- ★ Introduce new policies to provide for in-home care for children and young adults at end-of-life.
- ★ Advocate for additional funding for palliative care services in Budget 2022.
- ★ Work to ensure the views of patients, carers and family members on assisted dying are considered by Government through a respectful and consultative forum.
- ★ Review and implement improvements to our Night Nursing process and procedures, so that we can deliver the service more effectively and reach more people.



We provided almost 7,700 nights of night nursing to people with cancer in 2020, up 13% from 2019

Structured for impact

Our Goal

is to be a high performing organisation with the right people, culture, processes and technology in place, and to achieve more through effective partnerships.


Our strategy requires us to be structured well to effect change and support people affected by cancer. Along with sustainable fundraising, this is the enabler which will help us to achieve our strategy.

Some of what we have done in 2020

- ★ Almost 2,700 **volunteers** gave their time to support people affected by cancer in 2020, in addition to the thousands of volunteers who signed up to support Daffodil Day street sales, which unfortunately had to be cancelled in 2020. Due to COVID-19 restrictions, some of our volunteers had to take a break from volunteering during 2020, and we on-boarded more than 500 new volunteers to allow our vital services to keep running.
- ★ We founded a **Children and Young Adults Cancer Advisory Group** with other CAYA cancer organisations to better work in partnership. Our impact for children and young adults affected by cancer, and their families, is most powerful when we work together.
- ★ We established a **Grassroots Advocacy Champions**, with 26 Advocacy Champions across 26 Dáil constituencies already in place. This network will champion change in Irish cancer services, and be a voice for people affected by cancer in Ireland. Despite only forming in late 2020, the group contacted 70 TDs in 2020, to campaign on causes such as the impact of COVID-19 on cancer services, the COVID-19 vaccination rollout schedule, hospital car parking charges, and the use of debt collection agencies by hospitals.
- ★ We transitioned much of our workforce to **remote working**, in response to COVID-19, with no interruption to service delivery or key activities.
- ★ We implemented a new **programme and project management** structure in the Society, so that we can better run and manage projects, as well as track and measure our performance to deliver our strategy.

In 2021 we will...

- ★ Roll-out a new Volunteer Management policy and processes, to provide a best-in-class volunteer experience to our volunteers including additional training, support and supervision. We look forward to welcoming back all volunteers who had to take a step back due to COVID-19, and who are the lifeblood of our Society.
- ★ Launch an Oireachtas Working Group on Cancer, to provide a forum for the voice of people affected by cancer, and cancer experts, to be heard by Oireachtas members.
- ★ Expand the Grassroots Advocacy Network to all Dáil constituencies with all advocates trained and ready to drive change for people affected by cancer, and expand our network of online champions.
- ★ Devise, and implement, a People Strategy for the Society to develop and support our people to deliver the strategy.
- ★ Implement changes to our internal processes to better utilise technology, increase efficiency, and improve the quality of the services we offer.



2,700

Almost 2,700 volunteers gave their time to support people affected by cancer in 2020

How We Work



Our volunteers and staff

Volunteers are the backbone of the Society and our link to communities in every corner of Ireland. Every hour given, and donation raised, supports people affected by cancer.

Our volunteers engage across all of the Society's work. They help deliver services such as the Survivor Support programme, providing emotional and practical support to anyone going through cancer; the Volunteer Driver Service, bringing patients to and from chemotherapy appointments; and our Daffodil Centres, providing information and support. Volunteers also work across fundraising initiatives like Daffodil Day, Relay For Life and assisting in our retail shops; and in our advocacy and communications work, championing change and raising awareness. The Society's board and committee members all serve in a voluntary capacity providing governance, oversight and expertise.

Although 2020 was a very different year for our volunteers, COVID-19 didn't stand in their way of finding new and innovative ways to support our cause. Supporters across Ireland hosted virtual fundraisers and online collections, and new volunteers joined our services.

Sadly, due to COVID-19, some of our volunteers had to take a step back in 2020, for health reasons or to

comply with public health advice. We look forward to the time, hopefully not too far away, when they can join us again. To all who were part of our volunteer community in 2020 – thank you. Without your support, the Society's services wouldn't exist.

For our staff, 2020 was a year like no other. Across the Society our people adapted and responded to the challenges, to ensure that no-one had to go through cancer alone.

When Daffodil Centres were forced to close, our nurses redeployed to cancer wards in hospitals, so that patients still received the information, support and advice they needed. Despite COVID-19, our Night Nurses worked even more nights caring for people in their homes at end-of-life. Across the Society, staff adopted new technology, turned their kitchen tables into office desks, and took on new responsibilities, to make sure our support for people affected by cancer continued uninterrupted.

COVID-19 upended normal life for everyone. I want to thank the staff of the Irish Cancer Society, and my fellow volunteers, for how they stepped up for people affected by cancer in 2020. Their commitment and agility are key to our response to the ongoing challenges of the Pandemic

Brid Horan, Chair





Left: Daffodil Centre Nurse Milie Mathew providing cancer advice at a Daffodil Centre.

Middle: Night Nurse Mary Kavanagh dressed in PPE ahead of a night of care.

Right: Irish rugby player, Andrew Porter models the face mask he designed to raise funds for the Society.

Diversity and inclusion

Cancer affects everyone. As one of Ireland's largest charities, we champion diversity and inclusivity in all that we do. We listen to people across the cancer community, so we can provide information and services that cater to all needs. It doesn't matter who you are or where you come from, we are here for you.

Our initiatives across 2020 reached out to specific groups from all walks of life, including different ethnicities, people with disabilities and disadvantaged communities. We want to make sure all of our information is as accessible as possible. We use plain English, and provide different modes of access such as sign language interpreting for contacts to our Freephone Support Line, or patient information in different languages. As an employer, the Irish Cancer Society will also continue to celebrate diversity and equality in how we work.

Sustainability

We are committed to working in the most environmentally sustainable manner possible for the good of our planet and all who inhabit it.

This commitment shows in our everyday actions: we now use less paper as an organisation by providing our information materials on cancer digitally, where possible. Materials we do use are appropriately recycled. Our office lighting is powered by renewable energy and we have invested in energy-efficient fixtures and appliances. Plastic and single-use materials are kept to a minimum at our fundraising events, and Irish Cancer Society charity shops continue to offer a prime example of the benefits of a circular economy where items are reused rather than disposed of. Other sustainability efforts include encouraging cycling to work to increase physical exercise, which also helps to reduce emissions. And as a founding member of the Climate and Health Alliance, we will continue to work to address the crucial issue of climate change into the future.



Our partnerships

In order to deliver on our mission, the Irish Cancer Society partners with others across the cancer community, both nationally and internationally.

We work with health-related organisations including healthcare professionals and representative groups, national and global health organisations, health-related alliances, state agencies and bodies, risk factor alliances such as tobacco and alcohol groups, patient advocacy groups, health advocates and other charities. During 2020, we worked with the Irish Medical Organisation and the Irish College of General Practitioners to encourage people with symptoms of cancer to attend their GP's during the pandemic.

We want world-class cancer treatment for everyone, to achieve this, we partner with cancer researchers and research organisations, academia, global health institutes, and patient and public representatives. In 2020, we worked with the National Screening Service to develop an intervention aimed at increasing bowel screening uptake in Ireland. We partner with the National Cancer Control Programme, Ireland East Hospital Group and Mater Private Hospital through our Women's Health Initiative. To ensure that people affected by cancer are involved in making the decisions of which researchers we should fund, we work in partnership with patients on all of our research funding calls.

To ensure we can support everyone impacted by cancer in Ireland, we work with national agencies and organisations representing the diverse range of groups and communities nationwide.

We also work with organisations representing different industries including construction, farming, sporting and food agencies and with agencies representing workers' rights. Some of these include: the Construction Industry Federation, Teagasc, Irish Congress of Trade Unions, Irish Pharmacy Union, Men's Health Forum, Irish Dental Association, Spunout.ie, Safefood, and the Environmental Protection Agency.

We partner with and support community organisations including affiliated cancer centres, national and regional umbrella networks, and local delivery partners, to ensure everyone affected by cancer nationwide has access to the care and support they need, when they need it most.

We also have a variety of corporate fundraising partnerships with businesses across Ireland, who support our mission through employee fundraising initiatives, sponsorships and corporate donations.





Above: The Society's office is lit to commemorate the 9,000 lives lost to cancer in 2020.



Fundraising Review

On March 10th 2020, as a result of the evolving situation regarding COVID-19, the Society made the decision to cancel Daffodil Day 2020, its annual flagship fundraising event, which was scheduled to take place on March 27th.

This marked the first change to our fundraising calendar of activity, in a year where fundraising plans had to be completely rewritten. From this date onwards, all face-to-face fundraising events were cancelled.

2020 Objectives

- Raise €18.8 million from the public through donations, legacies and fundraising campaigns.
- Continue to diversify our income base and grow new sources of income.

How we did

2020 was a challenging year for fundraising due to the COVID-19 pandemic, however Irish Cancer Society supporters went above and beyond to ensure cancer patients still received the support they needed.

In 2020, together with our supporters €17.4 million was raised through donations, legacies and fundraising campaigns. Our work to grow new sources of income saw significant increases in digital and online fundraising events and donations.

Fundraising Campaigns

Fundraising campaigns such as Daffodil Day, Relay For Life and Cups Against Breast Cancer, went online and communities across Ireland came together whilst staying apart to support cancer patients and their families.

Weeks before Daffodil Day, the Society made the tough decision to cancel our flagship fundraiser, to ensure health and safety of our supporters and the general public. However, the public made sure that Daffodil Day still happened in some guise, and we were blown away by the extraordinary individual and virtual efforts made by the people of Ireland to continue the tradition. A virtual Daffodil Day was held, and thanks to the generosity of the Irish public, it raised over €1.8 million.

Despite restrictions, 12 Relay For Life communities across the country continued to celebrate cancer survivors and remember those lost to cancer, as they hosted virtual events and activities generating €350k. There was also recognition on the global stage with Relay For Life Wexford and Donegal team, Prancers Against Cancer both acknowledged with Standout Global Relay Awards awarded by the American Cancer Society.

Cups against Breast Cancer faced significant restrictions and struggled to reach its normal income levels, but thanks again to the support of the Irish public €120k was raised to support breast cancer patients and their families.

Throughout 2020, all active challenges were cancelled. However, this didn't stop our supporters taking their challenges online. Our virtual Colour Dash saw families across Ireland take on a colourful 5k run. More than 1,700 people also signed up to Marathon in a Month, taking on the distance of a marathon across the month of June, raising €500k. In addition to this, through the innovation of our supporters, other virtual active challenges raised €300k to support cancer patients in Ireland.




See more about

Our Fundraising Income

on page 44.





Top: National Campaigns Manager, Sinead Gillespie takes part in the Society's virtual 'Cups Against Breast Cancer' coffee morning.

Left: Adesola Botaji and Danielle Murray pictured promoting the Society's virtual campaign, Marathon in a Month, which had a record breaking year in 2020 raising over €600k!

Right: Presenters across the Communicorp network get in the festive spirit whilst hosting their Christmas 'Wear to Care' fundraiser.



Top: Louise O'Brien, Bobby Kerr, Owen Morgan, Averil Power and Elizabeth Arnett, at the 2020 corporate Daffodil Day launch, encouraging companies big and small to get involved and support Daffodil Day.

Left: Heroes from Home, the Society's first virtual gaming campaign, was launched in October 2020.



Community Fundraising

Alongside the Society's campaigns, hundreds of individual and groups across Ireland host activities and events in aid of the Irish Cancer Society. Despite restrictions, these supporters continued to find vibrant, fun and impactful ways to raise vital funds and awareness in their communities. Beyond making our work possible, these events helped foster a sense of community spirit and raise cancer awareness, at a time when our cancer community needed it most.

Committed Giving

The work of the Irish Cancer Society is made possible by a community of over 11,000 supporters who give a regular gift each month. Throughout 2020 over 700 new monthly supporters joined this community and made a long-term commitment to support our vital services. Every commitment provides us with sustainable funding to invest in the growth and continuation of our work for people affected by cancer.

Corporate Fundraising

Despite a challenging trading environment, our corporate partners continued to support us throughout the year. With remote working in place for many, companies found new and creative ways to help from home.

Boots Ireland was the main corporate sponsor of our 2020 Daffodil Day. Their staff, customers, family and friends continued to support Daffodil Day through sponsorship, in-store pin sales and employee fundraising. Boots' staff and customers also undertook a virtual Night Walk to fundraise for the Society's Night Nursing services.

For the first time ever, Marathon in a Month had a sponsorship partner, Ballygowan, whose support contributed hugely to the campaign's success.

Centra partnered with our Cups Against Breast Cancer campaign, selling pins in their stores throughout the month of October to raise awareness and funds for breast cancer care and research.

Once again we benefitted from Aldi Ireland's community support programme in 2020, through a combination of sponsorship of the virtual Colour Dash, staff donations and merchandise sales.

We were also very fortunate to be selected as Charity of the Year in 2020 by a number of organisations, including the Irish Management Institute, Twitter, and Chartered Accountants Ireland.

2021 Objectives

- ★ Optimise our channels and stewardship for digital fundraising.
- ★ Continue to minimise the impact of COVID-19 on our fundraising income.
- ★ Grow the Daffodil Day campaign through new messaging to reach new audiences and supporters and grow income.
- ★ Expand our regular giving offering.
- ★ Develop new strategic corporate partnerships.

The work of the Irish Cancer Society is made possible by a community of over 11,000 dedicated supporters who give a regular gift each month.



Financial Review

2020 was a challenging year for the Irish Cancer Society due to the many restrictions that were introduced as a result of the COVID-19 pandemic. In spite of this, and thanks to the help of its valued supporters, volunteers and employees, the Society managed to raise €21.9m.

In 2020, the Society's total income was €21.9m (2019: €24.3m), a decrease of €2.4m (10%) on prior year. The Society's total expenditure was €20.4m in 2020 (2019: €21.9m), a decrease of €1.5m (7%) on prior year.

Income

The vast majority of 2020 income came from the generous support of the public, through fundraising campaigns, donations, legacies and charity shop sales. Grants from the State represented only 7% of total income (2019: 3%).

Income	2020	2019
Donations And Legacies	€6.8m	€5.0m
Fundraising Campaign Income	€10.6m	€14.0m
Trading Activities	€1.9m	€3.8m
Charitable Activities	€1.9m	€1.4m
Other	€0.7m	€0.1m
Total Income	€21.9m	€24.3m

Impact of the COVID-19 pandemic on income

On 10 March 2020, as a result of the then unfolding situation regarding COVID-19, the Society made the decision to cancel Daffodil Day 2020, its annual flagship fundraising street and community based event, which was scheduled to take place on 27 March. All other face-to-face fundraising events were cancelled from this date onwards also. For the remainder of the year, the Society switched to running all its campaigns online, resulting in a 100% increase in digital income compared to 2019. In addition, all 21 of the Society's charity shops were closed for nearly five months of the year as a result of government restrictions.

Donations and legacies


Income from donations and legacies in 2020 was €6.8m. This was €1.8m higher than in 2019. Income from donations was €1.0m higher than in 2019, reflecting the overall increase in online donations. The Society's income from legacies increased by €0.8m in 2020; this increase follows a trend that the Society has noted in recent years.

Fundraising campaign income

Income from fundraising campaigns of €10.6m was €3.4m (24%) lower than 2019.

Due to the traditional community Daffodil Day being cancelled two weeks prior to when it was scheduled to take place, the campaign showed a 51% decrease when compared to 2019, bringing in a total of €1.8m (2019: €3.7m). In spite of the many challenges and restrictions, community events performed reasonably well and contributed a total of €2.8m in 2020 (2019: €3.4m); this was 18% lower than 2019. The Society managed to maintain its 2019 level of individual giving income at €3.3m. Income from corporate partnerships

2020 Fundraising Campaign Income



totalled €2.2m, a 14% decrease on 2019. The Society managed to bring in a total of €0.4m in relation to its Cups Against Breast Cancer, Shave or Dye, and Wear to Care virtual campaigns; this was a reduction of €0.6m when compared to 2019.

Trading activities

Income from the Society's 21 (2019: 20) charity shops decreased by €1.9m (50%) compared to 2019. This was as a result of the shops having been closed for nearly five months of 2020. Overall, the charity shops contributed a net deficit of €0.3m in 2020 (2019: net surplus of €1.0m).

Charitable activities

Income from charitable activities of €1.9m was €0.5m higher than in 2019. This income includes grants to support the Travel2Care and Night Nursing programmes, and reimbursements for Night Nursing services provided. The increase compared to 2019 relates to an additional grant of €0.4m having been received in relation to the Night Nursing service.

Other income

Other income of €0.7m was €0.6m higher than in 2019. This was due to the Society having availed of two COVID-19 related government schemes; the Temporary Wage Subsidy Scheme, and the Restart Grant Scheme.

Income from government agencies represented 7% of the Society's total income in 2020 (2019: 3%).

Expenditure

In 2020, the Society invested €20.4m (2019: €21.9m) in furtherance of its goals.

Expenditure	2020	2019
Charitable Activities	€14.4m	€13.7m
Fundraising Activities	€3.8m	€5.4m
Trading Activities	€2.2m	€2.8m
Total Expenditure	€20.4m	€21.9m

For every euro spent by the Society, 79c (2019: 72c) went on charitable activities (not including trading activities). A further 21c (2019: 28c) was spent by the Society to raise money to fund its charitable activities. This decrease was due to the Society having had to defer its door-to-door individual giving programme as a result of COVID-19 restrictions.

Charitable activities

Expenditure in relation to charitable activities in 2020 was €14.4m (2019: €13.7m), an increase of €0.7m (5%) in relation to 2019. This increase relates to a significant increase in demand for the Night Nursing service in 2020 as well as an investment by the Society in two new pilot services projects.


Fundraising activities

€3.8m was spent on fundraising activities (2019: €5.4m), a decrease of €1.6m (30%) on 2019 expenditure. This reduction was mainly due to the deferral of the Society's individual giving programme. For every euro spent on fundraising activities in 2020, the Society raised €4.50 in fundraising campaign income and donations and legacies (2019: €3.50).

Support costs

Support costs are costs which cannot be directly attributed to a particular activity and have been allocated accordingly. These include costs relating to information and technology, human resources, finance, governance and other central functions.

2020 Fundraising Campaign Direct Expenditure



These services play a crucial role in providing core organisational support in the delivery of the Society's charitable goals. The total support costs for the year were €2.9m (2019: €2.8m).

Trading activities

Trading activities spend was €2.2m, which was a decrease of €0.6m (22%) on 2019. The decrease was due to the closure of all 21 charity shops for five months of the year.

Financial Position and Reserves Policy

As the Society relies almost entirely on fundraised income, it needs to hold adequate reserves, so it can continue to provide critical services through challenging economic times, as well as take advantage of unexpected opportunities to improve the lives of those affected by cancer.

An adequate and working reserves policy provides essential accountability to the Society's beneficiaries, public supporters and other stakeholders, and assures them that the Society's activities are sustainable. The Society's reserves policy is framed to minimise liquidity risk. The Society has a policy of holding funds on deposit with its bankers, or investing in marketable securities, to ensure cash is available to meet liabilities as they arise.

The available resources at December 31, 2020 were €29.4m (2019: €27.4m). Of this, €0.5m (2019: €1.2m) was held in restricted funds, as the funds were donated for specific purposes. €1.0m (2019: €1.0m) was held in designated funds and €27.9m (2019: €25.2m) was held in unrestricted funds.

At December 31, 2020, the Society held 11.5 months (31 December 2019: 10.1 months) of expenditure (on a €25m expenditure basis) in cash and investments. During 2020, the Society launched a new ambitious 5 year strategy, and this level of cash and investments will allow expenditure on new programmes under the new strategy. The Society has budgeted for a deficit in 2021, and it expects to incur further deficits over the next 2-3 years as it invests in new initiatives to improve the lives of those affected by cancer. The current level of reserves will enable the Society to continue to deliver critical services to those affected by cancer, despite the uncertainty created by the COVID-19 pandemic.

Designated funds

The €1.0m fund at the year-end relating to research was held to protect currently committed research programmes from future unexpected variations in income. The time horizon on research programmes is typically three to five years.

Investment policy and performance

The investment policy supports the reserves policy. The Society requires working capital and adequate, appropriately accessible reserves to provide a buffer from income fluctuations.

The Society seeks to maintain an amount equivalent to approximately 6 months of annual expenditure in cash and investments. However, the actual amount maintained in cash and investments will vary depending on short and medium-term needs, as well as on income forecasts and the prevailing investment climate. It is the Society's policy not to invest, directly or indirectly, in tobacco, alcohol or sunbed companies. Investments are made within ethical guidelines, balancing risk and return, with capital preservation taking precedence over potential return. The Society's aim is to ensure that its investments maintain their capital value in real terms across the investment cycle. The majority of the Society's investments are held in securities which can be converted to cash very quickly. A review of both the reserves and investment policies is conducted regularly. During 2020, the Society's invested funds yielded an average return of +8.7% (2019: +11.0%). The Directors are satisfied with this level of return. There was a gain on investments of €0.5m in 2020 (2019: gain of €0.6m).

Accounting Records

The Directors have taken the following measures to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records: the employment of appropriately qualified accounting personnel and the maintenance of computerised accounting systems. The Society's accounting records are maintained at the Society's registered office at 43/45 Northumberland Road, Dublin 4.

Disclosure of Information to Auditors

In the case of each of the persons who are Directors at the time, the Directors' report and financial statements are approved;

- So far as the Director is aware, there is no relevant audit information of which the Society's auditors are unaware; and
- Each Director has taken all steps that ought to have been taken by the Director in order to make himself/herself aware of any relevant audit information and to establish that the Society's auditors are aware of that information.

The auditors, Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, continue in office in accordance with Section 383(2) of the Companies Act 2014.



Structure, Governance and Management

Organisational Structure

The Irish Cancer Society is a company limited by guarantee and registered as a charity with the Charities Regulatory Authority.

The Society is governed by its Constitution which provides for a member-based organisation with the following charitable aims:

- to foster, promote and advance the relief, cure, treatment, prevention, lessening and alleviation of cancer or any disease of an allied or similar nature.
- to promote research devoted to the study of the origin and causes, relief, cure, treatment, prevention, lessening and alleviation of cancer, or any disease of an allied or similar nature.

Members

There are currently 45 members of the Society, 9 of whom are Directors. Each member guarantees to contribute up to one euro twenty-seven cent (€1.27) to the Society's debts, liabilities and costs in the event of it being wound up.

Board of Directors

The Society has a voluntary Board of Directors which meets six times a year. The Directors are responsible for the governance and overall oversight of the organisation.

Day-to-day operational management is delegated to the Chief Executive Officer, Averil Power, who is supported by the Executive Leadership Team ("Management").

The Board manages its work through a number of committees, comprising Directors and external volunteers, each of which is chaired by a Director of the Board. The Society values the benefits of having committee members of varying backgrounds, expertise and experience.

Directors and committee members do not receive fees for their contribution to the Society but out-of-pocket expenses may be claimed.

Each year one third of Directors are subject to retirement by rotation. In 2020 Sinead Brennan offered herself for re-election and was duly re-elected. Dermot Breen, Sean Dorgan, Helen McEvoy, Fergus Brennan and Willie O'Reilly retired as Directors during 2020.

In addition, four new Directors were appointed to the Board in 2020. Ger Penny, Irene O'Gorman and Alex White were appointed in March 2020, and Brid Horan was appointed in July 2020.

In September 2020, after serving four years as Chair of the Board, Dermot Breen retired. The Board appointed Brid Horan as the new Chair. The Chair is elected annually by the Board for a maximum term of three years, which can be extended by a further one year in exceptional circumstances.

These new appointments strengthened the Board by bringing additional skills and expertise.

All new Directors receive an induction, overseen by Management. In 2020 we enhanced and strengthened our induction policy. Directors meet with the Chief Executive Officer, and other members of the Executive Leadership Team, and receive an overview of the Society's activities, the strategic plan, an outline of their statutory duties, and the Society's governance framework.

In 2021 the Board agreed a term limit for Directors of six years, which can be extended by the Board in exceptional circumstances, by a further three years, if such an extension serves the best interests of the Society. Three Directors serving over six years had their terms extended by one year to support Board continuity. Board committee members are appointed for three years, extendable by a further three years, at the discretion of the Board.

Board training is considered by the Chair and Company Secretary annually. Additionally, Board members are advised of relevant training opportunities as they arise.

Board evaluation

In 2020 the Board commissioned an independent external Board evaluation. The review concluded there was a strong governance structure in place and the Board was effective. All recommendations arising from the Board evaluation have now been implemented.

Conflict of interest

The Society has a conflict-of-interest policy and all Directors and external committee members sign a conflict-of-interest form annually. In addition, Directors sign a register-of-interests declaration. Conflict of interest is a standing agenda item at all committee meetings. If a committee member or a Director has a conflict of interest they must declare it to the committee, and they shall recuse themselves from that part of the meeting and have no part in the deliberation or decision.

The following Board and committee meetings were held in 2020:

Meetings held *	
Board of Directors	6
Finance Committee	6
Audit and Risk Committee	3
Board Effectiveness Committee	1
Research Advisory Committee	2

* A review of the Board committee structure was undertaken in 2020. Please see below for further details.

The following table shows Directors for the financial year 2020 and their attendance at Board meetings during the year. In addition, it shows Directors' appointment and retirement dates (where applicable).

Director	Attendance	Date of appointment	Date of retirement
Dermot Breen	4 of 4	09 Dec 08	17 Sep 2020
Fergus Brennan	1 of 1	28 Apr 16	30 Apr 2020
Dr Sinead Brennan	6 of 6	01 Sep 16	
Willie O'Reilly	4 of 4	29 Jun 11	01 Nov 2020
Andrew Craig	5 of 6	01 Jul 17	
Kieran Crowley	6 of 6	02 Oct 14	
Sean Dorgan	2 of 2	26 Jun 14	25 Jun 2020
Prof Liam Grogan	3 of 6	22 Nov 12	
Dr Cormac Kilty	5 of 6	19 Feb 15	
Dr Helen McAvoy	3 of 3	01 Sep 16	25 Jun 2020
Brid Horan	3 of 3	13 July 20	
Ger Penny	5 of 5	05 Mar 20	
Alex White	5 of 5	25 Mar 20	
Irene O'Gorman	5 of 5	25 Mar 20	

Executive Leadership Team

The management team is led by Chief Executive Officer, Averil Power, and they manage day-to-day operations of the Society.

The current Management team is made up of the following positions:

- CEO, Averil Power
- Director of Finance & Organisational Development, Conor King
- Director of Services Delivery & Innovation, Donal Buggy
- Director of Research, Dr Robert O'Connor
- Director of Advocacy & External Affairs, Rachel Morrogh
- Director of Fundraising & Engagement, Fionnuala O'Leary

Conor King was appointed as Acting CEO, from July 2020 until March 2021, while the CEO was on maternity leave.

Matters such as policy, strategic planning and budgets are drafted by Management for consideration and approval by the Board, which then monitors the implementation of these plans.



Board Committees

In 2020 the Board oversaw a review of its Board committee structure to ensure alignment with the Society's Strategic Plan 2020-2025. Arising out of this a new Board Effectiveness Committee was created, to replace the Governance and Nominating Committee, whilst the Cancer Support and Cancer Prevention Committees were stepped down. These changes were approved by the Board in September 2020.

As part of the review, the terms of reference for all Board committees were updated and approved by the Board.

Finance Committee

The Finance Committee exercises, on behalf of the Board, supervisory oversight of all aspects of the Society's finances. It monitors financial performance and oversees management of the investment portfolio on an ongoing basis. It also reviews the annual budget for recommendation to the Board.

Report of 2020 activity: During 2020 the Finance Committee monitored the Society's monthly management accounts, including income and expenditure trends, investment performance and reserve levels. It also oversaw the 2021 budgeting process, and was notified of any significant payments. Additionally, the Committee reviewed trading performance of the Society's 21 charity shops and reviewed the financial implications of the COVID-19 pandemic on the Society's operations.

Finance Committee Attendance 2020

Fergus Brennan *	2 of 2
Ger Penny (Chair)	5 of 6
Sean Dorgan *	3 of 3
Jane Neill	5 of 6
Irene O'Gorman *	3 of 3

* In April 2020, Fergus Brennan retired as Chair of the Finance Committee and was replaced by Ger Penny. In June 2020, Sean Dorgan retired from the committee and Irene O'Gorman was appointed as a member in August 2020.

Audit and Risk Committee

The Audit and Risk Committee assists the Board in fulfilling its responsibilities by independently reviewing the annual financial statements, overseeing the external audit, and reviewing the effectiveness of the Society's internal controls. It also monitors the Society's risk management, oversees regulatory and legislative compliance, and provides an assessment of risk processes and policies to the Board.

Report of 2020 activity: The Committee oversaw the Society's relationship with their external auditors, Deloitte. This included reviewing the workplan, considering Deloitte's key findings, including recommendations on internal controls, and ultimately recommending the Annual Report to the Board. The Committee also reviewed the Society's risk register. In addition, it oversaw a review of the Society's compliance with the Charities Regulator Governance Code, and considered key risks posed to the Society by COVID-19.

Audit & Risk Committee Attendance 2020

Andrew Craig (Chair)	3 of 3
Dr Cormac Kilty	3 of 3
Alex White	3 of 3

Board Effectiveness Committee

The Board Effectiveness Committee was established in late 2020, replacing the Governance and Nominating Committee. Its role is to oversee the nomination, recruitment, and on-going training, as necessary, of Directors, and support Board and sub-committee effectiveness.

Report of 2020 activity: The Committee met once in 2020. It considered Board succession, reviewed the Board's skills mix, and discussed the size, composition and diversity of the Board. It made recommendations to the Board on a rotation and tenure policy for Directors. It also considered how best to measure Board and sub-committee effectiveness.

Board Effectiveness Committee Attendance 2020

Brid Horan (Chair)	1 of 1
Ger Penny	1 of 1
Dr Cormac Kilty	1 of 1
Andrew Craig	1 of 1

Research Advisory Committee

The Research Advisory Committee reviews and evaluates the research activities and investments of the Society to ensure that they are achieving the objectives set out in the Society's strategic plan. It also ensures that the activities of the research department are in line with the national and international cancer research landscape, in addition to emerging clinical and patient needs.

Report of 2020 activity: The Committee met twice in the year. It reviewed the activities and plans for the research department, advised the Board on research elements in the new strategy and reviewed the research budget for 2021. The Committee oversaw and advised on the development of a 5 year research roadmap. It also provided guidance to the Society on how to make research investments that provide the greatest impact to those with cancer.

A strong governance culture ensures that the Society is best placed to deliver on its mission and achieve its objectives.



See more about

Our Board on
on page 53

Research Advisory Committee Attendance 2020

Dr Cormac Kilty (Chair)	2 of 2
Sir Alex Markham	2 of 2
Dr Susan Gapstur	2 of 2
Prof John Reynolds	2 of 2
Eileen O'Sullivan	2 of 2

Commitment to Best Practice in Corporate Governance

The Board operates to the highest governance standards and codes of conduct. A strong governance culture ensures that the Society is best placed to deliver on its mission and achieve its objectives. This is achieved by a continual focus on the Society's statutory and regulatory obligations, regular risk reviews, and by promoting a compliance-centric culture throughout the organisation.

During 2020 a full review of the Society's statutory, regulatory and compliance obligations was undertaken. The Board are satisfied that the Society is compliant with the *Charities Governance Code* and *Guidelines for Charitable Organisations on Fundraising from the Public*. In addition, the Society is compliant with relevant obligations under the Companies Act 2014 and the Charities Act 2009.

Directors' Compliance Statement

The Society is not required to prepare a Section 225 Compliance Statement (Companies Act 2014), for 2020. However, the Board and Management consider it best practice and so will continue to issue a compliance statement annually.

The Directors acknowledge that they are responsible for securing compliance by the Society of its relevant obligations as set out in Section 225 of the Companies Act.

The Directors further confirm that there is a Compliance Policy Statement in place setting out the Society's policies which, in the Directors' opinion, are appropriate to ensure compliance with the Society's relevant obligations.

For the year ended 31 December 2020 the Directors, with the assistance of the Audit and Risk Committee, have conducted a review of the arrangements and structures in place. Arising out of this the Directors can confirm that appropriate arrangements and structures are in place which, in the opinion of the Directors, are designed to secure material compliance with the company's relevant obligations.

Risk Management

The Society's risk management process is supported by its governance structure. Whilst the Directors are responsible for ensuring there is effective risk management and an appropriate internal control environment, Management are responsible for the day-to-day operation of its risk processes. Management monitors the level of risks on an ongoing basis and the Board reviews this regularly.

As part of the risk management process an annual risk review is undertaken. The aim of the review is to ensure that the Society is not exposed to an unacceptable level of preventable risk and to identify risk mitigation strategies. This was particularly important in 2020, as a result of the challenges posed by the emergence of COVID-19 to the Society, but also to cancer patients, and cancer services.

An in depth review of the risk register was undertaken by the Society in 2020. Each risk was reviewed by Management and updated with appropriate mitigation strategies.

The updated 2020 risk register was then considered by the Audit and Risk Committee and reported to the Board.



The following are the top five risks identified in 2020.

1. COVID-19 Risk:

The risk that the Society will fail to respond to cancer patients' needs and the emerging issues in cancer care, arising from COVID-19.

Mitigation measures

- Growing our feedback mechanisms with patients and key stakeholders.
- Adapting our services in 2020 to meet cancer patients' needs.
- Regular contact with key State stakeholders.
- Development of a Cancer Intelligence Unit.
- Timely and effective media campaigns.

2. Fundraising Risk:

The risk that the Society will not raise enough income to deliver its strategic objectives and meet the increased demand for its services.

Mitigation measures

- Close monitoring of fundraising income and targets on a monthly basis.
- Increased focus on digital fundraising and innovative funding streams.
- Ensuring appropriate communications to raise awareness of the brand.
- Development of a donor care strategy to optimise supporters' experience.

3. Information Security Risk:

The risk of a cybersecurity attack and data theft.

Mitigation measures

- Mandatory GDPR and IT security training for staff.
- Regular review of data protection policies, procedures and systems.
- Regular review of the Society's data recovery policies.
- Adopting new technologies to reduce cybersecurity threat.
- Working from home data risk assessment conducted.
- Cyber breach response plan being developed.

4. Services Provision Risk:

The risk that the Society's resources will not be sufficient to meet increased demand for services due to an increase in cancer incidence and increasing complexity of cancer diagnosis.

Mitigation measures

- Expansion and adaption of our services under our strategic implementation plan.
- Demand for services considered for annual budget process.
- Active monitoring of service users' unmet needs and requirements.
- Agile and responsive actions to meet challenges faced by patients and health care professionals in COVID-19 environment.

5. People Risk:

The risk that the Society will not be able to attract and retain talent at all levels including staff and Directors.

Mitigation measures

- Resource planning and organisational redesign underway as part of new Strategy.
- Adjustment of our performance management system.
- Internal communications plan developed and rolled out.
- Working from home policy in place and staff wellbeing surveys conducted.
- Commitment to a flexible working environment.
- Board succession planning in place.

The Board is satisfied that systems and processes are in place to monitor, manage and mitigate the Society's exposure to its major risks.



Directors' Responsibility Statement

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for ensuring that the company keeps, or causes to be kept, adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Legislation in Ireland governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

Approved by the Board and signed on its behalf by:



Brid Horan
Director



Andrew Craig
Director

Date: 1 July 2021



Our Board

Our Board of Directors strive to improve the lives of people affected by cancer. We asked each of them the following question:
What inspired you or motivated you to join the Board?



**Brid Horan,
Chair**

Brid is an independent Non-Executive Director experienced in executive roles and on public and private boards. Brid is currently Chair of Nephin Energy, Director of PM Group, Co-Chair Balance for Better Business and member of DCU Governing Authority. Brid was ESB Deputy Chief Executive until 2014 and served on the boards of IDA Ireland, FBD Holdings plc and National Pension Reserve Fund. She is an Actuary and Fellow IOD.

“ Like so many others, my life has been touched by cancer through very dear relatives and friends. The staff and volunteers of the Irish Cancer Society work tirelessly to support all those affected by cancer and I want to play my part.”



**Dr Sinead
Brennan**

Sinead is a Radiation Oncologist in St. Luke’s Hospital, Rathgar and in St. James’s Hospital, Dublin. She is Director of Research at St. Luke’s Radiation Oncology Network and St. Luke’s Institute of Cancer Research. She is Chair of the Head and Neck DSSG at Cancer Trials Ireland.

“ In my role as an oncologist, I am familiar with and admire the Irish Cancer Society’s work to support cancer patients and their families.”



**Kieran
Crowley**

Kieran is a Chartered Accountant and a Chartered Director. He is a Business Consultant advising Board and business owners on change, risk management, strategy and governance, with experience as a Board member in many companies.

“ The Society has thousands who volunteer to make things better for their friends and family hit with cancer, and that’s why I do it too.”



**Professor
Liam Grogan**

Liam is a Consultant Medical Oncologist in Beaumont Hospital and is an Honorary Clinical Associate Professor in the Royal College of Surgeons in Ireland.

“ I became involved in the Society to support its independent voice and caring hand, guiding cancer patients on their journey.”



Dr Cormac G Kilty

Cormac is a Biotech Entrepreneur retired from executive functions; managing a biotech investment portfolio and involved with two Angel Investment groups in Ireland. Cormac was a finalist for Ernst & Young Entrepreneur of the Year in 2004 and a recipient of an Honorary D.Sc. from UCD in 2000. He was voted one of the top 100 influential Ireland-US business leaders by Business & Finance in 2007 and 2008 and was awarded the US-Ireland Biolink award for contribution to Irish Life Sciences in 2007.

“ The Society’s research funding is a major contributor in training our oncology researchers for Ireland.”



Andrew Craig

Andrew retired after 30 years as a partner in PWC where he worked with a number of Ireland’s largest global companies and he also held a number of important leadership roles in PWC. Andrew is a Fellow of the Institute of Chartered Accountants in Ireland and is now a business advisor and non-executive director.

“ I intended to become involved in a not for profit organisation after retiring from PWC and I was very impressed with the people and work of the Irish Cancer Society.”



Ger Penny

Ger Penny is a qualified accountant and Chartered Director, with more than 25 years' experience in strategic and financial management in organisations across Ireland, the UK and Asia. He is CFO of the Sisk Group and a non-executive director of Uniphar plc.

“ The pandemic has shown to me the importance of the role that the Society plays in advocating the critical need to keep cancer care and prevention high on all stakeholders’ agendas.”



Irene O’Gorman

Irene is a highly experienced Chief Marketing Officer, currently with EY Ireland. Prior to that she has held marketing director roles with KPMG in the Middle East, Deloitte in Ireland and has also worked with firms in South Africa and Australia.

“ It’s a great honour to work with the Irish Cancer Society in support of a mutually shared vision, for a future without cancer.”




Alex White

Alex White SC is an experienced advocate and mediator, with a specialism in employment law. He is a former government Minister and TD. Prior to commencing legal practice he was a programme producer with RTÉ.

“ It’s a great honour to serve on the Board of the Irish Cancer Society, an organisation I have long admired for its unique combination of professionalism and genuine care. During this past difficult year, the staff and volunteers have succeeded in maintaining our services and our public visibility, for which they deserve enormous credit.”



Irish Cancer Society Organisation Chart



Financial Statements



Marie Masterson and Anita McGivney pictured at the launch of the Moylagh JFK 50 mile challenge in aid of the Irish Cancer Society at Fore Abbey Co. Westmeath.

Independent auditor's report to the members of Irish Cancer Society

Report on the audit of the financial statements

Opinion on the financial statements of Irish Cancer Society (the 'company')

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2020 and of its incoming resources and application of resources, including its income and expenditure for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Statement of Financial Activities;
- the Balance Sheet;
- the Cash Flow Statement; and
- the related notes 1 to 27, including a summary of significant accounting policies as set out in note 1.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council ("the relevant financial reporting framework").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual Report for the financial year ended 31 December 2020, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Report and Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Independent auditor's report (continued)

to the members of Irish Cancer Society

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the entity (or where relevant, the group) to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that the auditor identifies during the audit.

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Emer O'Shaughnessy
For and on behalf of
Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House, Earlsfort Terrace, Dublin 2

Date: 1 July 2021

Statement of financial activities


	Notes	2020 Unrestricted	2020 Restricted	2020 Designated	2020 Total	2019 Unrestricted	2019 Restricted	2019 Designated	2019 Total
		€'000	€'000	€'000	€'000	€'000	€'000	€'000	€'000
INCOME:									
Donations and legacies	3(a)	5,962	808	-	6,770	4,375	621	-	4,996
Fundraising campaign income	3(b)	8,897	1,716	-	10,613	11,224	2,713	-	13,937
Trading activities	3(c)	1,924	-	-	1,924	3,811	-	-	3,811
Investments	3(d)	92	-	-	92	60	-	-	60
Charitable activities	3(e)	908	960	-	1,868	780	657	-	1,437
Other income	3(f)	682	-	-	682	57	-	-	57
Total income		18,465	3,484	-	21,949	20,307	3,991	-	24,298
EXPENDITURE:									
Charitable activities	4	10,272	4,164	-	14,436	10,268	3,464	-	13,732
Fundraising activities	5	3,836	-	-	3,836	5,355	-	-	5,355
Trading activities		2,189	-	-	2,189	2,800	-	-	2,800
Total expenditure		16,297	4,164	-	20,461	18,423	3,464	-	21,887
Net gain on investments	13	545	-	-	545	554	-	-	554
Net income	9	2,713	(680)	-	2,033	2,438	527	-	2,965
Taxation	10	-	-	-	-	-	-	-	-
Transfers between funds	8	-	-	-	-	-	-	-	-
Net movement in funds		2,713	(680)	-	2,033	2,438	527	-	2,965
RECONCILIATION OF FUNDS:									
Funds balances brought forward		25,229	1,170	1,000	27,399	22,791	643	1,000	24,434
Funds balances carried forward		27,942	490	1,000	29,432	25,229	1,170	1,000	27,399

There are no other recognised gains or losses for the financial year except for those listed above. All income and expenditure derives from continuing operations.

Balance sheet

	Notes	2020 €'000	2019 €'000
Fixed Assets			
Tangible assets	12	9,135	9,335
Total Fixed Assets		9,135	9,335
Current Assets			
Investments	13	7,210	6,630
Stocks		222	51
Assets held for sale	14	-	510
Debtors: Amounts falling due within one year	15	1,872	1,250
Cash at bank and in hand		16,785	14,475
Total Current Assets		26,089	22,916
Creditors: Amounts falling due within one year	16	(3,510)	(3,172)
Net current assets		22,579	19,744
Total assets less current liabilities		31,714	29,079
Creditors: Amounts falling due after more than one year			
Long term liabilities	16	(2,282)	(1,680)
NET ASSETS		29,432	27,399
Funds:			
	8		
Restricted income funds		490	1,170
Designated income funds		1,000	1,000
Unrestricted income funds		27,942	25,229
TOTAL FUNDS		29,432	27,399

The financial statements were approved and authorised for issue by the board of directors on 1 July 2021 and signed on its behalf by:



Brid Horan
Director



Andrew Craig
Director

Statement of cash flows

	Notes	2020 €'000	2019 €'000
Cash flows from operating activities:			
Net cash generated by operating activities	19	3,133	4,396
Cash flows from investing activities:			
Deposit interest received		2	4
Purchase of fixed assets	12	(245)	(262)
Net cash flow from investing activities		(243)	(258)
Increase in cash and cash equivalents		2,890	4,138
Cash and cash equivalents at 1 January		21,105	16,967
Cash and cash equivalents at 31 December		23,995	21,105
Analysis of cash and cash equivalents			
Bank and cash		16,785	14,475
Cash equivalents		7,210	6,630
Cash and cash equivalents at 31 December		23,995	21,105

Notes to the financial statements

1. Accounting Policies

General Information

The purpose of the Irish Cancer Society is to improve the lives of those affected by cancer.

Irish Cancer Society is a not-for-profit company limited by guarantee with a charitable status. It is incorporated in the Republic of Ireland, with registration number of 20868. The address of its registered office is 43/45 Northumberland Road, Dublin 4. The Society is a public benefit entity.

Statement of Compliance

The financial statements of the Society for the year ended 31 December 2020 have been prepared in accordance with "the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland" ("FRS 102"), Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the FRS 102 (Charities SORP - FRS 102), and in accordance with the Irish statute comprising the Companies Act 2014.

Basis of Preparation

The financial statements have been prepared on a going concern basis, under the historical cost convention, modified to include the revaluation of investments to fair value. The financial statements have been prepared in accordance with Financial Reporting Standard 102, the financial reporting standard applicable in the UK and Republic of Ireland ("FRS102"), and voluntarily in accordance with the Statement of Recommended Practice, as applicable to charities preparing their accounts in accordance with FRS102 (issued by the Charity Commission for England and Wales, "the Charities SORP"). The presentation and functional currency of these financial statements is Euro.

Going Concern

The financial statements have been prepared on a going concern basis. The Directors have reviewed the 2020 Statement of Financial Activities and Balance Sheet, the approved 2021 budget and the latest financial information including an up to date forecast which takes into account the continued impact of the COVID-19 pandemic. The Directors are satisfied that the Society has adequate resources to continue in operational existence for the next 12 months, and as a result are satisfied that there are sufficient resources to manage any operational or financial risks. There is no material uncertainty that affects this assumption.

INCOME

Income is analysed in the Statement of Financial Activities under the following headings:

- Donations and legacies
- Fundraising campaign income
- Trading activities
- Investments
- Charitable activities
- Other Income

Income is recognised when the Society becomes entitled to the funds, receipt is probable and the amount can be quantified with reasonable accuracy.

Where income has not yet been received, but all criteria for recognition have been satisfied, the income is accrued as a debtor on the Balance Sheet. Where income has been received in advance, it is deferred as a creditor on the Balance Sheet until conditions are met.

Income arising from tax rebates is recognised on confirmation from the tax authorities of the amount and when there is certainty of receipt.

Grant income is recognised when the entitlement to the grant income is met. Income from grant agreements which are dependent on the provision of specific activities is recognised when the activity has been undertaken.

Donations and legacies

Donations are recognised when received.

Income arising from legacies is recognised when it becomes probable that funds will be received; i.e. where there is a grant of probate, the executors have established that there are sufficient assets in the estate and any conditions attached are within the control of the Society.

Donations-in-kind are recognised as income when received. Donations-in-kind are valued at open market value or at a reasonable estimate of the gross value to the Society.

Fundraising campaign income

Fundraising campaign income is recognised when received, or when all criteria for recognition have been satisfied.

Trading activities

Income from trading activities includes retail income from the sale of donated goods through shops.

Goods donated for resale are accounted for when they are sold rather than when they are donated because the high volume of low value items makes valuation impractical.

Charitable activities

Grants from government agencies and other entities relating to the Society's charitable activities are recognised as income when the Society is legally entitled to the income and has committed to fulfilling any conditions contained in the related funding agreements.

Other Income

Includes income received from government agencies that is not directly attributable to the Society's charitable activities. Other income is recognised when an entitlement to receipt has been met.

Notes to the financial statements (continued)

1. Accounting Policies (continued)

EXPENDITURE

Expenditure is analysed between charitable activities, fundraising activities and trading activities. The costs of each activity are separately disclosed and analysed according to their major components.

Expenditure is recognised when a legal or constructive obligation exists as a result of a past event, a transfer of economic benefits is required in settlement and the amount of the obligation can be reliably measured.

Support costs, which cannot be attributed directly to one activity, are allocated to activities on a headcount basis.

Governance costs, which are included within support costs, consist of direct expenditure and overhead costs incurred in relation to the strategic, as opposed to day-to-day management of the charity, and in relation to compliance with constitutional and statutory requirements. Costs related to audit and organisational risk management are also included in this category.

Redundancy and termination payments are recognised when there is a demonstrable commitment that cannot be realistically withdrawn.

Charitable Activities

Costs of charitable activities include costs of cancer awareness and prevention programmes and publications, services and support to improve the lives of cancer patients and survivors, collaborative research programmes and advocacy work, together with related support costs. All costs of charitable activities are recognised on an accruals basis.

Research and services grant costs are recognised in full in the year in which the commitment is made where there is an expectation that the full amount committed will be fully expended. When this is not certain, the costs are recognised over the term of the contract. Research and services grants are paid over the term of the grant agreement, and the outstanding balances at year-end are held under creditors on the Balance Sheet and split between current and long-term liabilities.

Expenditure in the form of grants to local partners is recognised on an accruals basis.

Fundraising activities

Fundraising activities comprise expenditure incurred on fundraising, including the costs of advertising, producing publications, printing and mailing fundraising material, staff costs and an appropriate allocation of support costs. All fundraising activities costs are recognised on an accruals basis.

Trading activities

Trading activities comprise expenditure incurred in relation to the Society's network of 21 charity shops. All trading activities costs are recognised on an accruals basis.

LEASES

Leases where substantially all the benefits and risks of ownership remain with the lessor are classified as operating leases. Payments made under operating leases are charged to the income statement on an accruals basis.

FUND ACCOUNTING

The Society maintains the following funds.

Restricted funds

Represent income that can only be used for a particular charitable purpose. Such restrictions are imposed by the donor or by the nature of the fundraising appeal.

Unrestricted funds

Represent income that can be used by the Society without restrictions. These funds are available to spend at the discretion of the Society in furtherance of its charitable objectives.

Designated funds

These are funds set aside at the discretion of the Directors for specific purposes. Any transfers to and from designated funds are approved by the Directors.

TANGIBLE FIXED ASSETS

Tangible assets are recognised when a resource is controlled by the Society as a result of a past event or transaction, it is probable that the expected future economic benefits associated with the asset will flow to the Society, and the historical or fair value can be reliably measured.

Tangible fixed assets are stated at cost less accumulated depreciation, and the carrying values are reviewed annually for impairment. Depreciation is provided for on all tangible fixed assets at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Freehold premises:	2.0% per annum
Fixtures and fittings:	10.0% per annum
Motor vehicles:	25.0% per annum
Furniture and equipment:	20.0% per annum
Computer equipment/software:	33.3% per annum

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Notes to the financial statements (continued)

1. Accounting Policies (continued)

INVESTMENTS

Listed investments are included on the Balance Sheet at fair value, which is their closing bid price on the current or previous trading day.

Unlisted investments are included on the Balance Sheet at their fair value. For unlisted funds this is based on the Society's share of the net asset value of the investments using the latest available performance data.

Investments are classified as current assets on the Balance Sheet as they can be converted to cash within three months.

Realised gains and losses on disposals in the year and unrealised gains and losses on investments at the Balance Sheet date are included in the Statement of Financial Activities for the relevant underlying funds.

All investment income is treated as unrestricted.

STOCK

Goods purchased for resale are stated at the lower of cost and estimated selling price less costs to complete and sell, which is equivalent to the net realisable value. Cost is defined as invoice price.

Unsold donated items are not included in closing stock since their cost is nil and their value is difficult to ascertain until sold.

ASSETS HELD FOR SALE

Gifted properties awaiting sale are valued at their fair value, which is their expected sale price less costs of sale and are valued by an independent valuer who holds a relevant professional qualification and has relevant experience of both the class and location of the asset.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash in hand, deposits with banks requiring less than three months' notice of withdrawal, and investments (excluding the investment in subsidiary).

FINANCIAL INSTRUMENTS

Financial assets and financial liabilities are recognised when the Society becomes a party to the contractual provisions of the instrument. Financial liabilities are classified according to the substance of the contractual arrangements entered into.

Financial instruments are recognised and measured in accordance with Section 11 of FRS 102.

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Society intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Trade and Other Debtors

Trade and other debtors are recognised at the settlement amount due after any discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

Trade and Other Creditors

Creditors and provisions are recognised where the Society has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be reliably measured or estimated. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due and at their present value where the time value of money is deemed significant.

RETIREMENT BENEFITS

The Irish Cancer Society operates a defined contribution ("DC") pension scheme. Contributions payable to this scheme are charged to the Statement of Financial Activities in the period to which they relate. Amounts not yet remitted at the year-end are included in accruals on the Balance Sheet. The assets of the plan are held separately from the Society in independently administered funds.

TAXATION

The Society has been granted an exemption under Sections 207 and 208 of the Taxes Consolidation Act 1997.

Notes to the financial statements (continued)

2. Critical Accounting Judgements and Key Sources of Estimation Uncertainty

In the application of the Society's accounting policies, which are described in Note 1, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The Directors do not consider there are any critical judgements or sources of estimation uncertainty in the application of the accounting policies in Note 1.

3. Income

a) Donations and legacies

	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Donations	2,255	430	2,685	1,751
Legacies	3,707	378	4,085	3,245
Total	5,962	808	6,770	4,996

Donations include general contributions, social media led event donations, tribute gifts in memory, and donations in lieu of wedding favours.

b) Fundraising campaign income

	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Community Daffodil Day	1,781	24	1,805	3,677
Community events	2,428	409	2,837	3,442
Individual giving	2,942	319	3,261	3,205
Corporate partnerships	1,359	835	2,194	2,556
Cups Against Breast Cancer	-	126	126	530
Shave or Dye and Dare to Care	285	3	288	446
Christmas cards	102	-	102	81
Total	8,897	1,716	10,613	13,937

Community events include local fundraising, challenge events and Relay for Life.

Notes to the financial statements (continued)

3. Income (continued)

c) Trading activities	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Shop income	1,911	-	1,911	3,798
Other trading activities	13	-	13	13
Total	1,924	-	1,924	3,811
d) Investments	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Investment income	91	-	91	56
Deposit interest	1	-	1	4
Total	92	-	92	60
e) Income from charitable activities	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
NCCP Travel to Care	-	350	350	507
Other State income	2	607	609	150
Total government grants	2	957	959	657
Night Nursing reimbursements				
Malignant	50	-	50	23
Non-malignant	839	-	839	727
Total reimbursements	889	-	889	750
Other	17	3	20	30
Total	908	960	1,868	1,437
f) Other income	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
VAT Compensation Scheme	68	-	68	57
Covid-19 Government subsidies and grants	614	-	614	-
Total	682	-	682	57

Notes to the financial statements (continued)

4. Analysis of Expenditure on Charitable Activities

The table below analyses direct and support costs. Direct costs are the delivery costs of an activity including direct salaries. Support costs are analysed in Note 6.

	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Reduce the Risk of Cancer				
Cancer prevention campaigns & literature	191	140	331	408
Cancer action communities	46	-	46	54
Youth advocacy	8	-	8	39
Operating costs	489	-	489	490
Total direct and operating costs	734	140	874	991
Support costs	295	-	295	288
Total Reduce the risk of cancer	1,029	140	1,169	1,279
Improve Lives - Survivorship				
Support group affiliation	475	49	524	481
Volunteer Drivers	174	104	278	339
Travel2Care (NCCP)	-	326	326	333
Prostate awareness and support	152	-	152	260
Financial support	165	1	166	168
National conference for cancer survivors	37	-	37	64
Survivors supporting survivors	9	-	9	11
Pilot Services Grants	162	393	555	-
Operating costs	386	-	386	363
Total direct and operating costs	1,560	873	2,433	2,019
Support costs	295	-	295	288
Total Survivorship	1,855	873	2,728	2,307

Notes to the financial statements (continued)

4. Analysis of Expenditure on Charitable Activities (continued)

	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Improve Lives - Information & Support				
Night Nursing	1,893	1,743	3,636	3,072
Daffodil centres	739	187	926	1,068
Public and patient awareness	697	-	697	352
Cancer Nurseline	207	66	273	283
Patient literature	140	1	141	136
Professional support	17	-	17	40
Operating costs	321	-	321	203
Total direct and operating costs	4,014	1,997	6,011	5,154
Support costs	1,055	30	1,085	1,040
Total Information and support	5,069	2,027	7,096	6,194
Research				
Translational	582	148	730	-
Survivorship	5	396	401	666
Trials	508	500	1,008	591
Clinical and biomedical	(13)	-	(13)	1,051
Other research grants	153	80	233	567
Operating costs	451	-	451	458
Total direct and operating costs	1,686	1,124	2,810	3,333
Support costs	152	-	152	149
Total Research	1,838	1,124	2,962	3,482
Grants are analysed in Note 7.				
Advocacy				
Operating costs	329	-	329	321
Support costs	152	-	152	149
Total Advocacy	481	-	481	470
Total expenditure on charitable activities	10,272	4,164	14,436	13,732

Notes to the financial statements (continued)

5. Fundraising Activities

Costs comprise the following:

	2020 Unrestricted €'000	2020 Restricted €'000	2020 Total €'000	2019 Total €'000
Community Daffodil Day	467	-	467	645
Individual giving	284	-	284	1,309
Community events	245	-	245	501
Cups Against Breast Cancer	75	-	75	126
Corporate partnerships	48	-	48	65
Movember	-	-	-	7
Shave or Dye and Dare to Care	35	-	35	82
Total fundraising campaign costs	1,154	-	1,154	2,735
Donations	69	-	69	39
Legacies	14	-	14	24
Donations and Legacies costs	83	-	83	63
Operating costs	1,657	-	1,657	1,657
Total direct costs	2,894	-	2,894	4,455
Investment management costs	56	-	56	35
Support costs (Note 6)	886	-	886	865
Total	3,836	-	3,836	5,355

6. Support Costs

Support costs are the costs of personnel and associated information technology, finance, human resources and other central functions. Also included are the governance costs comprising the external annual audit and other legal and regulatory compliance.

Support costs are allocated across the Society's activities to fairly represent the cost of delivering those activities. The costs have been allocated on a headcount basis and are apportioned as follows:

- 58% to Improve Lives / Reduce Risk
- 31% to Fundraising
- 11% to Research and Advocacy

Notes to the financial statements (continued)

6. Support Costs (continued)

	2020 Improve Lives / Reduce Risk €'000	2020 Research and Advocacy €'000	2020 Fundraising €'000	2020 Total €'000	2019 Total €'000
Information Technology	529	96	281	906	880
Finance	343	57	172	572	510
Human Resources	244	41	122	407	330
Other	559	110	311	980	1,059
Total	1,675	304	886	2,865	2,779

Included in the support costs are the following governance costs:

	2020 €'000	2019 €'000
Legal and professional fees	38	1
Audit fees	29	29
Total	67	30

7. Research Grants

Expenditure on the following grants was charged in 2020:

Recipient	Project Description	€'000
Cancer Trials Ireland	Core and strategic funding to support cancer clinical trials in Ireland in 2020	500
Prof Donal Brennan	The Womens Health Initiative funding 2020. This project is focussed on improving care for women impacted by cancer treatment. Awarded to University College Dublin.	300
Prof Lydia Lynch	Irish Cancer Society Immuno-oncology Award 2020 for a project entitled "Novel immune activators for ovarian cancer". Awarded to Trinity College Dublin.	296
Dr Luke Jones	Translational Postdoctoral Fellowship 2020 for a project entitled "Using structure-based modelling to identify effective drug combinations in high-risk acute leukaemia". Awarded to University College Dublin.	223
Dr Eva Svegezdi	Funding for the Collaborative Cancer Research Centre Blood Cancer Network (BCNI) final year. Co-funded with Science Foundation Ireland. Awarded to the National University of Ireland, Galway.	208
Dr Nicholas Clarke	Increasing Bowel Screening Uptake Research Award 2020. Co-funded with the National Screening Service. Project entitled "Interventions to improve bowel cancer screening uptake in Ireland: a 2x2 factorial trial". Awarded to Dublin City University.	160
Dr Shirley Potter	Clinician Research Leadership Award - University College Dublin.	150

Notes to the financial statements (continued)

7. Research Grants (continued)

Recipient	Project Description	€'000
Dr Dearbhaile Collins	Clinician Research Leadership Award - University College Cork.	150
Dr Alice le Bonniec	Social, Nursing & Allied Health Science Fellowship 2020 for a project entitled "Increasing bowel screening uptake: development of an innovative intervention for a better prognosis". Awarded to the National University of Ireland, Galway.	149
Adele Connor	Translational Research PhD Scholarship 2020 for a project entitled "Investigating the heterogeneous biology of ovarian cancer metastases by high-resolution imaging to inform novel combination therapies". Awarded to University College Dublin.	148
Dr Paul Walsh	National Cancer Registry Ireland 2020-2021 Fellowship for "Measuring breast cancer progression and recurrence in a cancer registry".	96
Dr Emma Allott	Additional funding awarded for a project entitled "Role of lipids in Treatment Response and Prostate Cancer Specific Outcomes". Awarded to Trinity College Dublin.	42
Dr Antoinette Perry	Support for the 56th Irish Association for Cancer Research Annual Conference 2020 in Galway.	14
Beth McKeague (NUI Maynooth) and Christina Gleeson (NUI Galway)	Social, Nursing and Allied Health Research Summer Studentships 2020.	5
Dr Roisin Loftus, TCD	Investigating How the Source of Dietary Fat Shapes Anti-Cancer Immune Cell Responses in Obesity	4
Mobility	Total mobility grants 2020	14
Various	Prior years Grants unused / cancelled and returned	(100)
Operating Costs	Management of tenders, review and oversight	451
Total direct costs		2,810
Support and central costs	(Note 4)	152
Total		2,962

The summary above includes the commitments entered into and recognised in 2020. Grant recipients typically receive payments over the period of the grant which is determined by the conditions of the underlying agreement. During the year 120 researchers worked on research projects funded by the Society (2019: 134).

The process for guiding the nature of research grants is overseen by the Research Advisory Committee. Typically the Society issues a grant call for a particular subject area and sets the selection criteria. The Society then appoints an independent panel of experts and patient representatives to adjudicate the submissions based on the Society's selection criteria. Grant recipients are required to send progress reports to the Society at set milestones, and the payment of instalments is dependent on the receipt of satisfactory progress reports. The results of research projects funded by the Society are typically published in reputable research or medical journals and the Society's contribution is noted therein. Research may also be used to inform developments in health system and practice, for example outlining hurdles to accessing care or improving outcome.

Notes to the financial statements (continued)

8. Analysis of Charitable Funds

a) Analysis of Movement in Designated Funds

The designated fund comprises amounts allocated by the Directors from unrestricted income.

The €1.0m fund relating to research is held to protect currently committed research programmes from future unexpected variations in income.

	Opening Balance as at 01/01/2020 €'000	Income/ Expenditure 2020 €'000	Transfers 2020 €'000	Closing Balance as at 31/12/2020 €'000
Research	1,000	-	-	1,000

b) Analysis of Movement in Restricted Funds

Restricted funds are funds received where the donor has specified how the funds are to be used.

	Opening Balance as at 01/01/2020 €'000	Income 2020 €'000	Expenditure 2020 €'000	Transfers 2020 €'000	Closing Balance as at 31/12/2020 €'000
Breast cancer	545	575	(1,117)	-	3
Prostate cancer	-	50	(50)	-	-
Travel2Care grants (State)	359	350	(326)	-	383
Research	175	896	(1,028)	-	43
Nursing	-	1,350	(1,350)	-	-
Paediatric cancer	-	1	(1)	-	-
Survivorship	-	23	(23)	-	-
Reduce the risk	-	140	(140)	-	-
Cancer Information Services	91	-	(30)	-	61
COVID-19	-	99	(99)	-	-
Total	1,170	3,484	(4,164)	-	490

Breast Cancer: to fund information, advice, research and support services for women and men affected by breast cancer.

Prostate Cancer: to fund information, advice, research and support services for men affected by prostate cancer.

Travel2Care: to fund financial assistance for patients who travel to hospital appointments.

Research: to fund vital cancer research programmes to deliver new hope and supports for patients, enabling new therapies, and building an advanced cancer research infrastructure which will enhance the country's cancer care capabilities into the future.

Nursing: to fund support to patients who need end-of-life care through a home nursing service and to fund advice and guidance through our Cancer Nurseline and Daffodil Centres.

Paediatric cancer: to fund research and support services (including financial support) for children affected by cancer.

Notes to the financial statements (continued)

8. Analysis of Charitable Funds (continued)

Survivorship: to fund a support network to cancer survivors through annual conferences, peer-to-peer educational and wellbeing programmes in affiliated cancer support centres, funding counselling for survivors, providing patient transport through Volunteer Drivers programme.

Reduce the Risk: to fund programmes aimed at raising awareness and sharing information on how to avoid cancer.

Cancer Information Services: to fund the provision of the Society's online platform in order to enhance the Society's ability to disseminate cancer related information.

COVID-19: to fund additional expenditure associated with the COVID-19 pandemic such as personal protective equipment for nurses and the provision of remote services to people affected by cancer.

c) Analysis of Movement in Unrestricted Funds

Unrestricted funds are funds received where the donor has not specified how the funds are to be used.

	Opening Balance as at 01/01/2020 €'000	Income 2020 €'000	Expenditure 2020 €'000	Transfers 2020 €'000	Gains 2020 €'000	Closing Balance as at 31/12/2020 €'000
General fund	25,229	18,465	(16,297)	-	545	27,942

d) Analysis of Net Assets Between Funds

	Restricted Funds €'000	Designated Funds €'000	General Funds €'000	Total 2020 €'000
Tangible fixed assets	-	-	9,135	9,135
Current assets	490	1,000	24,599	26,089
Current and long-term liabilities	-	-	(5,792)	(5,792)
Total	490	1,000	27,942	29,432

In respect of prior year:

	Restricted Funds €'000	Designated Funds €'000	General Funds €'000	Total 2019 €'000
Tangible fixed assets	-	-	9,335	9,335
Current assets	1,170	1,000	20,746	22,916
Current and long-term liabilities	-	-	(4,852)	(4,852)
Total	1,170	1,000	25,229	27,399

Notes to the financial statements (continued)

9. Net Income for the Financial Year

	2020 €'000	2019 €'000
This is stated after charging:		
Depreciation	444	435
Auditor's remuneration:		
- Audit of financial statements	29	29
- Other assurance services	5	4
- Tax advisory services	4	2
- Other non-audit services	96	-
Directors' remuneration	-	-
Operating lease charge	594	624

The Directors all serve in a voluntary capacity and do not receive any remuneration.

10. Taxation

No charge to corporation taxation arises as the Society has been granted exemption under Sections 207 and 208 of the Taxes Consolidation Act 1997.

11. Employees and Remuneration

The Society employs staff to deliver on its strategy, raise income and provide infrastructure and support. Staff costs are allocated to the following activities: charitable activities, fundraising, charity shops and support.

The average number of persons (on a full-time equivalent basis) employed by the Society during the financial year is set out below:

	2020 Number	2019 Number
Charitable activities	56	58
Charitable activities – Night Nursing	46	37
Fundraising	25	28
Charity shops	28	43
Support	27	25
Total	182	191

Notes to the financial statements (continued)

II. Employees and Remuneration (continued)

Night Nursing:

The Society employs Night Nurses to provide free end-of-life care in patients' homes. In 2020 194 (2019: 197) nurses were employed for at least one night by the Society with an average of 80 nurses working each week (2019: 78). This equates to 46 (2019: 37) nurses on a full-time equivalent basis.

The aggregate payroll costs were as follows:

	2020 €'000	2019 €'000
Salaries	9,910	9,259
Social welfare costs	918	970
DC pension scheme employer contributions (Note 20)	434	460
Permanent health, life assurance and DC pension scheme costs	185	179
Total	11,447	10,868

Included in the 2020 remuneration figures above are redundancy costs of €357,163 relating to eight people (2019: €777 relating to one person).

Employee remuneration (excluding pension, redundancy and end-of-contract holiday pay) exceeding €70,000:

	2020 Number	2019 Number
€70,001 - €80,000	2	3
€80,001 - €90,000	2	1
€90,001 - €100,000	3	5
€100,001 - €110,000	1	1
€110,001 - €120,000	1	-
€120,001 - €130,000	-	-
€130,001 - €140,000	-	1
> €140,000	-	-

Key management personnel is defined as the CEO and the members of the executive leadership team. The total emoluments (including benefits, pension and redundancy) paid to key management personnel in 2020 was €733,367 (2019: €737,300).

In 2020 the CEO was paid a salary of €110,367 (2019: €125,000) and a car allowance of €7,910 (2019: €10,000). The Society contributed 15% (2019: 20%) of the CEO's salary to the defined contribution pension scheme.

Director expenses:

Directors receive no remuneration for their services. Out-of-pocket expenses incurred in connection with their duties may be claimed. In 2020 the Society made payments of €Nil (2019: €733) in relation to out-of-pocket expenses.

Notes to the financial statements (continued)

12. Tangible Assets

	Freehold Premises	Fixtures & Fittings	Motor Vehicles	Furniture & Equipment	Computer Equipment & Software	Total
	€'000	€'000	€'000	€'000	€'000	€'000
Cost:						
At 01/01/2020	13,283	203	19	638	1,296	15,439
Additions	-	34	-	9	202	245
Disposals	-	-	-	(1)	(4)	(5)
At 31/12/2020	13,283	237	19	646	1,494	15,679
Depreciation:						
At 01/01/2020	4,197	163	19	529	1,197	6,105
Charge for financial year	265	13	-	32	134	444
Disposals	-	-	-	(1)	(4)	(5)
At 31/12/2020	4,462	176	19	560	1,327	6,544
Net book amounts: At 31/12/2020	8,821	61	-	86	167	9,135
Net book amounts: At 31/12/2019	9,085	42	-	108	100	9,335

Included in freehold premises is a property that is used for trading activities; a section of this property that is currently surplus to operational requirements, is rented to a third party on a short-term commercial basis. The rental income from this property in 2020 was €13,000 (2019: €13,000) and is included under other trading activities in Note 3. The other 20 shops are held on a leasehold basis.

Notes to the financial statements (continued)

13. Current Asset Investments

	2020 €'000	2019 €'000
At 1 January	6,630	5,228
Gain/(loss) on investments	545	554
Bequeathed investment additions	-	827
Investment income	91	56
Management fees	(56)	(35)
At 31 December	7,210	6,630

	2020 €	2019 €
Investment in Subsidiary (Note 23):		
At 1 January	1	1
Impairment loss	-	-
At 31 December	1	1

The Irish Cancer Society has an investment in a subsidiary undertaking as follows:

100% of the shares of Irish Cancer Society Research Limited.

The directors believe the carrying value of the investments is supported by their underlying net assets. The net assets of Irish Cancer Society Research Limited were €3 in 2020 (2019: €3).

Investment funds are included in the accounts at fair value and any fluctuations are accounted for in the Statement of Financial Activities.

14. Assets Held For Sale

	31/12/2020 €'000	31/12/2019 €'000
Balance at 1 January	510	537
Bequeathed property additions	-	-
Bequeathed property disposals	(510)	-
Impairment charge	-	(25)
Increase in cost to sell	-	(2)
Balance at 31 December	-	510

Included in assets held for sale at 31 December 2019 is a property which was bequeathed to the Society during 2019. The property was disposed of in January 2020.

Notes to the financial statements (continued)

15. Debtors: Amounts falling due within one year

	2020 €'000	2019 €'000
Trade and other debtors	783	104
Accrued income	696	691
221+ support group balance due	-	59
Prepayments	393	396
Total	1,872	1,250

All trade debtors are due within the Society's normal terms, which is typically 30 days.

16. Creditors

Amounts falling due within one year:

	2020 €'000	2019 €'000
Trade and other creditors	549	524
Accruals	682	395
221+ support group funds held in trust	5	-
Payroll taxes	283	239
Instalments due on research and services grants payable	1,991	2,014
Total	3,510	3,172

The repayment terms of trade creditors vary between on demand and 90 days.

The 221+ support group funds held in trust balance relates to funds held on behalf of 221+CCG Cervical Cancer Association Company Limited.

Amounts falling due after more than one year:

	2020 €'000	2019 €'000
Instalments due under research and services grants payable	2,282	1,680

Notes to the financial statements (continued)

17. Grant Commitments And Provisions

	31/12/2020 €'000	31/12/2019 €'000
Balance at 1 January	3,694	2,667
New grants awarded	3,010	2,964
Grants refunded	(88)	(89)
Grants disbursed	(2,343)	(1,848)
Balance at 31 December	4,273	3,694

Classified as:

Due within 1 year	1,991	2,014
Due after 1 year	2,282	1,680
Balance at 31 December	4,273	3,694

18. Financial Instruments

The carrying values of the Society's financial assets and liabilities are summarised by category below:

	2020 €'000	2019 €'000
Financial Assets		
Measured at fair value through profit or loss		
Current asset listed investments (see Note 13)	7,210	6,630
Measured at undiscounted amount receivable		
Trade and other debtors (see Note 15)	783	104
Total	7,993	6,734

Financial Liabilities

Measured at undiscounted amount payable Trade and other payables (see Note 16)	4,827	4,218
--	-------	-------

The Society's income, expense, gains and losses in respect of financial instruments are summarised below:

	2020 €'000	2019 €'000
Fair value gains and (losses)		
On financial assets measured at fair value through statement of financial activity	545	554

Notes to the financial statements (continued)

19. Cash Flow Statement

a) Reconciliation of changes in net income to cash generated by operations

	2020 €'000	2019 €'000
Net income for the financial year	2,033	2,965
Adjustments for:		
Depreciation	444	435
Loss on disposal of fixed assets	-	2
Increase / (decrease) in creditors	938	826
(Increase) / decrease in stock	(169)	1
(Increase) / decrease in assets held for sale	510	27
(Increase) / decrease in debtors	(622)	144
Deposit interest	(1)	(4)
Cash generated by operations	3,133	4,396

b) Net debt

The Society had no borrowings or obligations under finance leases as at 31 December 2020 (2019: none).

20. Retirement Benefit Schemes

Defined Contribution Scheme

The Society operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the organisation in an independently administered fund. The organisation made contributions of €434,325 (2019: €459,636) during the financial year. The amount outstanding at the financial year end was €77,938 (2019: €81,424). The outstanding balances are held on the Balance Sheet under creditors.

21. Constitution

The liability of the members of the Society to contribute towards its assets is limited to an amount not to exceed the sum of €1.27 in each case.

22. Operating Leases

The future minimum lease payments under operating leases for each of the following periods:

At 31 December the Society had total commitments under operating leases in relation to charity shops premises, storage and office space:

	2020 €'000	2019 €'000
Within one year	562	582
Between one and five years	1,720	1,892
More than five years	389	606
Total	2,671	3,080

Notes to the financial statements (continued)

22. Operating Leases (continued)

At 31 December the Society has total rental income under operating leases in relation to a premises rented out:

	2020	2019
	€'000	€'000
Within one year	2	13
Between one and five years	-	2
More than five years	-	-
Total	2	15

23. Financial Assets

The Society's subsidiary, Irish Cancer Society Research Limited, was incorporated in Ireland in 1991 and the address of its registered office is 43-45 Northumberland Road, Dublin 4. Irish Cancer Society Research Limited was engaged in the business of sale of Christmas cards. The Company ceased trading at the end of 2013. As Irish Cancer Society Research Limited did not trade during 2020 and has insignificant net assets, consolidated financial statements have not been prepared.

24. Related Parties

There were no related party transactions in 2020.

25. Post Balance Sheet Events

There have been no events subsequent to the year-end that require any adjustment to, or additional disclosure in, the 2020 financial statements.

26. Political Donations

The Society made no political donations during 2020.

27. Approval of Financial Statements

These financial statements were approved by the board on 1 July 2021

Reference and administrative details

Reference

Within this document the Irish Cancer Society is referred to as the Society and the Company.

Company Number

20868

Charity Regulator Number

20009502

Revenue Charity Number

5863

Registered Office

43/45 Northumberland Road, Dublin 4

Company Directors

Dermot Breen (resigned 17 September 2020)

Fergus Brennan (resigned 30 April 2020)

Dr Sinead Brennan

Andrew Craig

Kieran Crowley

Sean Dorgan (resigned 25 June 2020)

Prof Liam Grogan

Brid Horan (appointed 13 July 2020)

Dr Cormac Kilty

Dr Helen McAvoy (resigned 25 June 2020)

Irene O’Gorman (appointed 25 March 2020)

Willie O’Reilly (resigned 01 November 2020)

Ger Penny (appointed 05 March 2020)

Alex White (appointed 25 March 2020)

Chair

Brid Horan

Chief Executive

Averil Power

Company Secretary

Conor King

Bankers

AIB Bank, 9 Terenure Road, Rathgar, Dublin 6

Solicitors

Hayes Solicitors, Lavery House, Earlsfort Terrace, Dublin 2

Investment Advisers

Brewin Dolphin Capital & Investments (Ireland) Limited, The Harcourt Building, Harcourt Street, Dublin 2

Auditors

Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, Deloitte and Touche House, Earlsfort Terrace, Dublin 2







Irish Cancer Society
43/45 Northumberland Road
Dublin 4, Ireland

T: +353 (01) 231 0500
E: info@irishcancer.ie

www.cancer.ie

